UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
 
 
x

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2014MARCH 31, 2015
 
 ¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM             TO             
Commission file number:              1-1136
 
 BRISTOL-MYERS SQUIBB COMPANY
(Exact name of registrant as specified in its charter)
   
Delaware 22-0790350
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
 
345 Park Avenue, New York, N.Y. 10154
(Address of principal executive offices) (Zip Code)
 
(212) 546-4000
(Registrant’s telephone number, including area code)
 
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to the filing requirements for the past 90 days.    Yes  x   No  ¨
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer”, “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer  x    Accelerated filer  ¨    Non-accelerated filer  ¨    Smaller reporting company  ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No x
APPLICABLE ONLY TO CORPORATE ISSUERS:
At September 30, 2014March 31, 2015, there were 1,658,776,4911,666,974,545 shares outstanding of the Registrant’s $0.10 par value common stock.

 



BRISTOL-MYERS SQUIBB COMPANY
INDEX TO FORM 10-Q
SEPTEMBER 30, 2014MARCH 31, 2015
 
  
PART I—FINANCIAL INFORMATION 
  
Item 1. 
Financial Statements:
 
Consolidated Statements of Earnings
3
Consolidated Statements of and Comprehensive Income
43
Consolidated Balance Sheets
54
Consolidated Statements of Cash Flows
65
Notes to Consolidated Financial Statements
76
  
Item 2. 
Management’s Discussion and Analysis of Financial Condition and Results of Operations
2621
  
Item 3. 
Quantitative and Qualitative Disclosure About Market Risk
3934
  
Item 4. 
Controls and Procedures
3934
  
PART II—OTHER INFORMATION 
  
Item 1. 
Legal Proceedings
3934
  
Item 1A. 
Risk Factors
3934
  
Item 2. 
Issuer Purchases of Equity Securities
4035
  
Item 6. 
Exhibits
4136
  
Signatures
4237




PART I—FINANCIAL INFORMATION
Item  1. FINANCIAL STATEMENTS
BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF EARNINGS
Dollars and Shares in Millions, Except Per Share Data
(UNAUDITED)

 Three Months Ended September 30, Nine Months Ended September 30,
EARNINGS2014 2013 2014 2013
Net product sales$2,843
 $3,025
 $8,420
 $9,006
Alliance and other revenues1,078
 1,040
 3,201
 2,938
Total Revenues$3,921
 $4,065
 $11,621
 $11,944
        
Cost of products sold1,007
 1,175
 2,966
 3,346
Marketing, selling and administrative1,029
 980
 2,937
 3,016
Advertising and product promotion171
 194
 521
 601
Research and development983
 893
 3,345
 2,774
Other (income)/expense(277) 5
 (589) 185
Total Expenses2,913
 3,247
 9,180
 9,922
        
Earnings Before Income Taxes1,008
 818
 2,441
 2,022
Provision for Income Taxes276
 126
 439
 177
Net Earnings732
 692
 2,002
 1,845
Net Earnings Attributable to Noncontrolling Interest11
 —
 11
 8
Net Earnings Attributable to BMS$721
 $692
 $1,991
 $1,837
        
Earnings per Common Share       
Basic$0.43
 $0.42
 $1.20
 $1.12
Diluted$0.43
 $0.42
 $1.19
 $1.11
        
Cash dividends declared per common share$0.36
 $0.35
 $1.08
 $1.05
The accompanying notes are an integral part of these consolidated financial statements.

3
 Three Months Ended March 31,
EARNINGS2015 2014
Net product sales$3,059
 $2,807
Alliance and other revenues982
 1,004
Total Revenues$4,041
 $3,811
    
Cost of products sold847
 968
Marketing, selling and administrative894
 957
Advertising and product promotion135
 163
Research and development1,016
 946
Other (income)/expense(299) (208)
Total Expenses2,593
 2,826
    
Earnings Before Income Taxes1,448
 985
Provision for Income Taxes249
 49
Net Earnings1,199
 936
Net Earnings/(Loss) Attributable to Noncontrolling Interest13
 (1)
Net Earnings Attributable to BMS$1,186
 $937
    
Earnings per Common Share   
Basic$0.71
 $0.57
Diluted$0.71
 $0.56
    
Cash dividends declared per common share$0.37
 $0.36



BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Dollars in Millions
(UNAUDITED)

Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
COMPREHENSIVE INCOME2014 2013 2014 20132015 2014
Net Earnings$732
 $692
 $2,002
 $1,845
$1,199
 $936
Other Comprehensive Income/(Loss), net of taxes and reclassifications to earnings:          
Derivatives qualifying as cash flow hedges57
 (31) 49
 7
6
 (3)
Pension and postretirement benefits(407) 232
 (508) 956
(44) (114)
Available for sale securities(22) 14
 (7) (32)
Available-for-sale securities16
 2
Foreign currency translation(8) (7) 2
 (41)31
 (11)
Other Comprehensive Income/(Loss)(380) 208
 (464) 890
9
 (126)
          
Comprehensive Income352
 900
 1,538
 2,735
1,208
 810
Comprehensive Income Attributable to Noncontrolling Interest11
 —
 11
 8
Comprehensive Income/(Loss) Attributable to Noncontrolling Interest13
 (1)
Comprehensive Income Attributable to BMS$341
 $900
 $1,527
 $2,727
$1,195
 $811
The accompanying notes are an integral part of these consolidated financial statements.


3



BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEETS
Dollars in Millions, Except Share and Per Share Data(UNAUDITED)
ASSETSMarch 31,
2015		 December 31,
2014
Current Assets:   
Cash and cash equivalents$6,294
 $5,571
Marketable securities1,313
 1,864
Receivables3,458
 3,390
Inventories1,437
 1,560
Deferred income taxes1,885
 1,644
Prepaid expenses and other538
 470
Assets held-for-sale—
 109
Total Current Assets14,925
 14,608
Property, plant and equipment4,323
 4,417
Goodwill7,027
 7,027
Other intangible assets1,706
 1,753
Deferred income taxes685
 915
Marketable securities4,279

4,408
Other assets634
 621
Total Assets$33,579
 $33,749
    
LIABILITIES   
    
Current Liabilities:   
Short-term borrowings$330
 $590
Accounts payable2,346
 2,487
Accrued expenses1,791
 2,459
Deferred income1,459
 1,167
Accrued rebates and returns910
 851
Income taxes payable220
 262
Dividends payable633
 645
Total Current Liabilities7,689
 8,461
Pension, postretirement and postemployment liabilities1,156
 1,115
Deferred income697
 770
Income taxes payable638
 560
Other liabilities583
 618
Long-term debt7,127
 7,242
Total Liabilities17,890
 18,766
    
Commitments and contingencies (Note 17)
 
    
EQUITY   
    
Bristol-Myers Squibb Company Shareholders’ Equity:   
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued   
and outstanding 4,191 in 2015 and 4,212 in 2014, liquidation value of $50 per share—
 —
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2015   
and 2014221
 221
Capital in excess of par value of stock1,314
 1,507
Accumulated other comprehensive loss(2,416) (2,425)
Retained earnings33,110
 32,541
Less cost of treasury stock – 541 million common shares in 2015 and 547 million in 2014(16,683) (16,992)
Total Bristol-Myers Squibb Company Shareholders’ Equity15,546
 14,852
Noncontrolling interest143
 131
Total Equity15,689
 14,983
Total Liabilities and Equity$33,579
 $33,749
The accompanying notes are an integral part of these consolidated financial statements.

4



BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED BALANCE SHEETSSTATEMENTS OF CASH FLOWS
Dollars in Millions Except Share and Per Share Data(UNAUDITED)
(UNAUDITED)

ASSETSSeptember 30,
2014		 December 31,
2013
Current Assets:   
Cash and cash equivalents$4,851
 $3,586
Marketable securities2,370
 939
Receivables3,321
 3,360
Inventories1,565
 1,498
Deferred income taxes1,510
 1,701
Prepaid expenses and other482
 412
Assets held-for-sale78
 7,420
Total Current Assets14,177
 18,916
Property, plant and equipment4,387
 4,579
Goodwill7,046
 7,096
Other intangible assets1,718
 2,318
Deferred income taxes1,015
 508
Marketable securities4,328

3,747
Other assets779
 1,428
Total Assets$33,450
 $38,592
    
LIABILITIES   
    
Current Liabilities:   
Short-term borrowings and current portion of long-term debt$401
 $359
Accounts payable2,568
 2,559
Accrued expenses2,290
 2,152
Deferred income995
 756
Accrued rebates and returns914
 889
Income taxes payable312
 160
Dividends payable623
 634
Liabilities related to assets held-for-sale—
 4,931
Total Current Liabilities8,103
 12,440
Pension, postretirement and postemployment liabilities806
 718
Deferred income810
 769
Income taxes payable552
 750
Deferred income taxes93
 73
Other liabilities618
 625
Long-term debt7,267
 7,981
Total Liabilities18,249
 23,356
    
Commitments and contingencies (Note 19)
 
    
EQUITY   
    
Bristol-Myers Squibb Company Shareholders’ Equity:   
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued   
and outstanding 4,227 in 2014 and 4,369 in 2013, liquidation value of $50 per share—
 —
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2014   
and 2013221
 221
Capital in excess of par value of stock1,499
 1,922
Accumulated other comprehensive loss(2,605) (2,141)
Retained earnings33,147
 32,952
Less cost of treasury stock – 549 million common shares in 2014 and 559 million in 2013(17,119) (17,800)
Total Bristol-Myers Squibb Company Shareholders’ Equity15,143
 15,154
Noncontrolling interest58
 82
Total Equity15,201
 15,236
Total Liabilities and Equity$33,450
 $38,592
 Three Months Ended March 31,
 2015 2014
Cash Flows From Operating Activities:   
Net earnings$1,199
 $936
Adjustments to reconcile net earnings to net cash provided by operating activities:   
Net (earnings)/loss attributable to noncontrolling interest(13) 1
Depreciation and amortization, net104
 137
Deferred income taxes(7) 110
Stock-based compensation54
 49
Impairment charges13
 47
Pension settlements and amortization50
 80
Gain on sale of businesses and other(234) (262)
Changes in operating assets and liabilities:   
Receivables(91) 107
Inventories51
 (144)
Accounts payable(83) (12)
Deferred income334
 327
Income taxes payable81
 (215)
Other(832) (544)
Net Cash Provided by Operating Activities626
 617
Cash Flows From Investing Activities:   
Proceeds from sale and maturities of marketable securities1,508
 376
Purchases of marketable securities(821) (1,080)
Additions to property, plant and equipment and capitalized software(136) (118)
Business divestitures and other proceeds203
 3,055
Business acquisitions and other payments—
 (21)
Net Cash Provided by Investing Activities754
 2,212
Cash Flows From Financing Activities:   
Short-term borrowings, net(260) (79)
Repayments of long-term debt—
 (676)
Interest rate swap contract terminations27
 (4)
Issuances of common stock174
 172
Dividends(623) (605)
Net Cash Used in Financing Activities(682) (1,192)
Effect of Exchange Rates on Cash and Cash Equivalents25
 2
Increase in Cash and Cash Equivalents723
 1,639
Cash and Cash Equivalents at Beginning of Period5,571
 3,586
Cash and Cash Equivalents at End of Period$6,294
 $5,225
The accompanying notes are an integral part of these consolidated financial statements.

5



BRISTOL-MYERS SQUIBB COMPANY
CONSOLIDATED STATEMENTS OF CASH FLOWS
Dollars in Millions
(UNAUDITED)

 Nine Months Ended September 30,
 2014 2013
Cash Flows From Operating Activities:   
Net earnings$2,002
 $1,845
Adjustments to reconcile net earnings to net cash provided by operating activities:   
Net earnings attributable to noncontrolling interest(11) (8)
Depreciation and amortization, net364
 582
Deferred income taxes(57) (409)
Stock-based compensation147
 140
Impairment charges386
 6
Gain on sale of businesses and other(560) (11)
Changes in operating assets and liabilities:   
Receivables(66) (563)
Inventories(162) (8)
Accounts payable63
 301
Deferred income404
 702
Income taxes payable82
 128
Other(16) (570)
Net Cash Provided by Operating Activities2,576
 2,135
Cash Flows From Investing Activities:   
Proceeds from sale and maturities of marketable securities2,771
 1,520
Purchases of marketable securities(4,811) (1,448)
Additions to property, plant and equipment and capitalized software(335) (337)
Proceeds from sale of businesses3,277
 8
Other investing activities(37) —
Net Cash Provided by/(Used in) Investing Activities865
 (257)
Cash Flows From Financing Activities:   
Short-term debt borrowings, net45
 488
Proceeds from issuance of long-term debt—
 12
Repayments of long-term debt(676) (597)
Interest rate swap contract terminations(4) —
Issuances of common stock229
 483
Repurchases of common stock—
 (433)
Dividends(1,800) (1,732)
Net Cash Used in Financing Activities(2,206) (1,779)
Effect of Exchange Rates on Cash and Cash Equivalents30
 16
Increase in Cash and Cash Equivalents1,265
 115
Cash and Cash Equivalents at Beginning of Period3,586
 1,656
Cash and Cash Equivalents at End of Period$4,851
 $1,771
The accompanying notes are an integral part of these consolidated financial statements.

6




Note 1. BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS

Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS or the Company) prepared these unaudited consolidated financial statements following the requirements of the Securities and Exchange Commission (SEC) and United States (U.S.) generally accepted accounting principles (GAAP) for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Form 10-Q. These consolidated financial statements include all normal and recurring adjustments necessary for a fair presentation of the financial position at September 30, 2014March 31, 2015 and December 31, 20132014, and the results of operations for the three and nine months ended September 30, 2014 and 2013, and cash flows for the ninethree months ended September 30, 2014March 31, 2015 and 2013.2014. All intercompany balances and transactions have been eliminated. These unaudited consolidated financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 20132014 included in the Annual Report on Form 10-K (2013(2014 Form 10-K).

Certain prior period amounts were reclassified to conform to the current period presentation. Net product sales and alliance and other revenues previously presented in the aggregate as net sales in the consolidated statements of earnings are now presented separately.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates and assumptions. The most significant assumptions are employed in estimates used in determining the fair value and potential impairment of intangible assets; sales rebate and return accruals; legal contingencies; income taxes; estimated selling prices used in multiple element arrangements; and pension and postretirement benefits. Actual results may differ from estimated results.

Certain prior period amounts were reclassified to conform to the current period presentation. Pension settlements and amortization previously presented in Other in the consolidated statements of cash flows are now presented separately.

In April 2014, the Financial Accounting Standards Board (FASB) issued amended guidance on the use and presentation of discontinued operations in an entity's consolidated financial statements. The new guidance restricts the presentation of discontinued operations to business circumstances when the disposal of business operations represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The guidance becomesbecame effective on January 1, 2015. Adoption is on a prospective basis.

In May 2014, the FASB issued a new standard related to revenue recognition, which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The new standard will replace most of the existing revenue recognition standards in U.S. GAAP when it becomes effective on January 1, 2017. Early adoption is not permitted. The new standard can be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of the change recognized at the date of the initial application in retained earnings. The Company is assessing the potential impact of the new standard on financial reporting and has not yet selected a transition method.

Note 2. BUSINESS SEGMENT INFORMATION

BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are utilized and responsible for the development and delivery of products to the market. Regional commercial organizations distribute and sell the products. The business is also supported by global corporate staff functions. Segment information is consistent with the financial information regularly reviewed by the chief executive officer for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods.

Product revenues were as follows:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Virology          
Baraclude (entecavir)(a)
$325
 $378
 $1,100
 $1,115
$340
 $406
Hepatitis C Franchise(b)(a)
49
 —
 49
 —
264
 —
Reyataz (atazanavir sulfate)338
 375
 1,044
 1,167
Reyataz (atazanavir sulfate) Franchise294
 344
Sustiva (efavirenz) Franchise(c)(b)
357
 389
 1,037
 1,187
290
 319
Oncology          
Erbitux* (cetuximab)187
 183
 542
 516
165
 169
Opdivo (nivolumab)(d)
1
 —
 1
 —
40
 —
Sprycel (dasatinib)385
 316
 1,095
 915
375
 342
Yervoy (ipilimumab)350
 238
 942
 700
325
 271
Neuroscience          
Abilify* (aripiprazole)(e)(c)
449
 569
 1,544
 1,654
554
 540
Immunoscience          
Orencia (abatacept)444
 375
 1,209
 1,047
400
 363
Cardiovascular          
Eliquis (apixaban)216
 41
 493
 75
355
 106
Diabetes Alliance(f)
42
 432
 248
 1,228
Mature Products and All Other(g)
778
 769
 2,317
 2,340
Mature Products and All Other(d)
639
 951
Total Revenues$3,921
 $4,065
 $11,621
 $11,944
$4,041
 $3,811
*Indicates brand names of products which are trademarks not owned or wholly owned by BMS. Specific trademark ownership information can be found at the end of this quarterly report on Form 10-Q.
(a)Includes generic sales of entecavir from a U.S. supply and distribution agreement with Par Pharmaceutical Companies, Inc.
(b)
Includes Daklinza (daclatasvir) revenues of $38$180 million for the three and nine months ended September 30, 2014, and includes Sunvepra (asunaprevir) revenues of $11$84 million for the three and nine months ended September 30, 2014.March 31, 2015.
(c)(b)Includes alliance and other revenue of $309$251 million and $328$272 million for the three months ended September 30,March 31, 2015 and 2014, and 2013, respectively, and $894 million and $998 million for the nine months ended September 30, 2014 and 2013, respectively.
(d)Includes alliance and other revenue from our alliance with Ono Pharmaceutical Company Ltd. in Japan.
(e)(c)
Includes alliance and other revenue of $410$508 million and $464$441 million for the three months ended September 30,March 31, 2015 and 2014, and 2013, respectively, and $1,350 million and $1,313 million for the nine months ended September 30, 2014 and 2013, respectively.

(f)(d)
Includes Bydureon* (exenatide extended-release for injectable suspension), Byetta* (exenatide), Farxiga*/Xigduo* (dapagliflozin/dapagliflozin and metformin hydrochloride), Onglyza*/Kombiglyze* (saxagliptin/saxagliptin and metformin), Myalept* (metreleptin) and Symlin* (pramlintide acetate). BMS sold its diabetes business to AstraZeneca on February 1, 2014.
(g)
Includes Plavix* (clopidogrel bisulfate)Diabetes Alliance revenues of $44$54 million and $42$179 million for the three months ended September 30,March 31, 2015 and 2014, and 2013, respectively, and $137 million and $177 millionrespectively. See "—Note 3. Alliances" for further information on the nine months ended September 30, 2014 and 2013, respectively. Additionally, includes Avapro*/Avalide* (irbesartan/irbesartan-hydrochlorothiazide) revenues of $56 million and $71 million for the three months ended September 30, 2014 and 2013, respectively, and $171 million and $173 million for the nine months ended September 30, 2014 and 2013, respectively.
diabetes business divestiture.

Note 3. ALLIANCES

BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and are exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. We refer to these collaborations as alliances and our partners as alliance partners. Several key products such as Abilify*, Sprycel, Sustiva (Atripla*), Erbitux*, Eliquis and EliquisOpdivo, as well as products comprising the diabetes alliance discussed belowin the 2014 Form 10-K and certain mature and other brands are included in alliance arrangements.


76



Selected financial information pertaining to our alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized.
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Revenues from alliances:          
Net product sales$816
 $1,100
 $2,493
 $3,177
$994
 $895
Alliance and other revenues958
 969
 2,909
 2,736
955
 912
Total Revenues$1,774
 $2,069
 $5,402
 $5,913
$1,949
 $1,807
          
Payments to/(from) alliance partners:          
Cost of products sold$338
 $337
 $1,016
 $964
$389
 $355
Marketing, selling and administrative31
 (28) 34
 (97)12
 (3)
Advertising and product promotion6
 (34) 73
 (56)13
 35
Research and development(20) (38) (55) (93)122
 (16)
Other (income)/expense(411) (66) (964) (238)(301) (395)
          
Noncontrolling interest, pre-tax7
 (4) 18
 19
5
 4

Selected Alliance Balance Sheet information:      
Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Receivables - from alliance partners$1,061
 $1,122
$956
 $888
Accounts payable - to alliance partners1,766
 1,396
1,482
 1,479
Deferred income from alliances(a)
1,515
 5,089
1,647
 1,493

(a)Included deferred income classified as liabilities related to assets held-for-sale of $3,671 million at December 31, 2013.

Specific information pertaining to each of our significant alliances is discussed in our 20132014 Form 10-K, including their nature and purpose, the significant rights and obligations of the parties, and specific accounting policy elections. Significant developments and updates related to alliances during the ninethree months ended September 30, 2014March 31, 2015 are set forth below.

AstraZeneca

In February 2014, BMS and AstraZeneca terminated their alliance agreements and BMS sold to AstraZeneca substantially all of the diabetes business comprising the alliance. Previously, BMS had an alliance with AstraZeneca consisting of three worldwide codevelopment and commercialization agreements covering (1) Onglyza* and related combination products sold under various names, (2) Farxiga* and related combination products and, (3) beginning in August 2012 after BMS's acquisition of Amylin Pharmaceuticals, Inc. (Amylin), Amylin's portfolio of products including Bydureon*, Byetta*, Symlin* and Myalept*, as well as certain assets owned by Amylin, including a manufacturing facility located in West Chester, Ohio.

The divestiture included the shares of Amylin and the resulting transfer of its Ohio manufacturing facility; the intellectual property related to Onglyza*/Kombiglyze* and Farxiga*/Xigduo* (including BMS's interest in the out-licensing agreement for Onglyza* in Japan); and the future purchase of BMS’s manufacturing facility located in Mount Vernon, Indiana in 2015. 2015 (expected to close in the third quarter). Amylin's portfolio of products include Bydureon*, Byetta*, Symlin* and Myalept*. Substantially all employees dedicated to the diabetes business were transferred to AstraZeneca. The sale of the business has been completed in all jurisdictions. For accounting purposes AstraZeneca is the principal for the end-customer product sales in all markets.

In connection with the sale, BMS and AstraZeneca entered into several agreements, including a transitional services agreement, a supply agreement and a development agreement. Under those agreements, BMS is obligated to provide transitional services such as accounting, financial services, customer service, distribution, regulatory, development, information technology and certain other administrative services for various periods in order to facilitate the orderly transfer of the business operations; to supply certain products, including the active product ingredients for Onglyza* and Farxiga* through 2020; and to perform ongoing development activities for certain clinical trial programs through 2016, among other things. The annual costs attributed to the development agreement are not expected to exceed approximately $227 million in 2014, $127 million in 2015 and $84 million in 2016.


8



Consideration for the transaction includes a $2.7 billion payment at closing; contingent regulatory and sales-based milestone payments of up to $1.4 billion (including $800 million related to approval milestones and $600 million related to sales-based milestones, payable in 2020); royalty payments based on net sales through 2025 and payments up to $225 million if and when certain assets are transferred to AstraZeneca. AstraZeneca will also pay BMS for any required product supply at a price approximating the product cost as well as negotiated transitional service fees.

Royalty rates on net sales are as follows:
 2014201520162017 - 2025
Onglyza* and Farxiga* Worldwide Net Sales up to $500 million
44%35%27%12-25%
Onglyza* and Farxiga* Worldwide Net Sales over $500 million
3%7%9%12-25%
Amylin products U.S. Net Sales—
2%2%5-12%

The stock and asset purchase agreement contains multiple elements to be delivered subsequent to the closing of the transaction, including the China diabetes business (transferred during the third quarter of 2014), the Mount Vernon, Indiana manufacturing facility, and the activities under the development and supply agreements. Each of these elements was determined to have a standalone value. As a result, a portion of the consideration received at closing was allocated to the undelivered elements using the relative selling price method after determining the best estimated selling price for each element. The remaining amount of consideration was included in the calculation for the gain on sale of the diabetes business. Contingent milestone and royalty payments are similarly allocated among the underlying elements if and when the amounts are determined to be payable to BMS. Amounts allocated to the sale of the business are immediately recognized in the results of operations. Amounts allocated to the other elements are recognized in the results of operations only to the extent each element has been delivered.

Consideration of $3.8 billion was accounted for in 2014, substantially all in the first quarter (including royalties and $700 million of contingent regulatory milestone payments related to the approval of Farxiga* in both the U.S. and Japan). Approximately $3.3 billion of the consideration was allocated to the sale of the business and the remaining $491 million was allocated to the undelivered elements described above. The gain on sale of the diabetes business was $539 million, including $292 million during the third quarter of 2014 resulting primarily from the transfer of the China diabetes business to AstraZeneca. The gain was based on the difference between the consideration allocated to the sale of the business (net of transaction fees) and the carrying value of the diabetes business net assets (including a $600 million allocation of goodwill and the reversal of $821 million of net deferred tax liabilities attributed to Amylin). The consideration includes $226 million of earned royalties, of which $184 million was allocated to the sale of the business and included in other income and $42 million was allocated to the undelivered elements.

Consideration allocated to the Mount Vernon manufacturing facility will continue to be deferred until transferred to AstraZeneca. Consideration allocated to the development and supply agreements will continue to be amortized over the applicable service periods. Amortization of deferred income attributed to the development agreement was included in other income as the sale of these services are not considered part of BMS’s ongoing major or central operations. Revenues attributed to the supply agreement were included in alliance and other revenues.

Consideration for the transaction is presented for cash flow purposes based on the allocation process described above, either as an investing activity if attributed to the sale of the business or related assets or as an operating activity if attributed to the transitional services, supply arrangement or development agreement.

97



Summarized financial information related to the AstraZeneca alliances was as follows:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Revenues from AstraZeneca alliances:          
Net product sales$2
 $429
 $163
 $1,216
$—
 $160
Alliance and other revenues40
 3
 85
 12
54
 19
Total Revenues$42
 $432
 $248
 $1,228
$54
 $179
          
Payments to/(from) AstraZeneca:          
Cost of products sold:          
Profit sharing$1
 $169
 $78
 $493
$—
 $76
Amortization of deferred income—
 (78) —
 (227)
          
Cost reimbursements to/(from) AstraZeneca recognized in:          
Cost products sold—
 (10) (9) (19)
Cost of products sold—
 (9)
Marketing, selling and administrative—
 (30) (7) (101)—
 (11)
Advertising and product promotion—
 (10) (4) (28)—
 (3)
Research and development(1) (21) (10) (64)—
 (7)
          
Other (income)/expense:          
Amortization of deferred income(23) (8) (57) (23)(24) (13)
Provision for restructuring—
 4
 (2) (21)—
 (2)
Royalties(46) —
 (184) —
(81) (48)
Transitional services(18) —
 (83) —
(3) (31)
Gain on sale of business(292) —
 (539) —
(5) (259)
          
Selected Alliance Cash Flow information:          
Deferred income19
 —
 308
 80
1
 275
Proceeds from sale of business94
 —
 3,248
 —
Other investing activities114
 —
 167
 —
Business divestitures and other proceeds12
 3,055
Selected Alliance Balance Sheet information:      
Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Deferred income attributed to:      
Non-refundable upfront, milestone and other licensing receipts(a)
$—
 $3,671
Assets not yet transferred to AstraZeneca176
 —
$180
 $176
Services not yet performed for AstraZeneca250
 —
207
 226

(a)Included in liabilities related to assets held-for-sale at December 31, 2013.
Otsuka
BMS's commercialization rights to Abilify* in European Union (EU) countries expired in June 2014.
As described in the 20132014 Form 10-K, BMS recognizes revenue forreceives a share of U.S. net sales of Abilify* in the U.S.based on a tiered structure and recognizes revenues based on the expected annual contractual share using a forecast of net sales for the year. BMS's U.S rights to Abilify* expired on April 20, 2015. The percentage is estimated each quarter and determinedtotal annual revenues for 2015 are expected to be within the first tier of 50%. The estimated annual contractual share was 33% and 34% for the ninethree months ended September 30, 2014March 31, 2014.

In February 2015, BMS terminated the co-promotion agreement with Otsuka in Japan with respect to Sprycel. It is not expected to have a material impact on future results.

Lilly

BMS has an Epidermal Growth Factor Receptor (EGFR) commercialization agreement with Eli Lilly and 2013, respectively.Company (Lilly) through Lilly’s subsidiary ImClone for the co-development and promotion of
Gilead
As describedErbitux* in the 2013 Form 10-K, effective January 1, 2014, followingU.S., Canada and Japan. Under the European loss of exclusivityEGFR agreement, both parties actively participate in a joint executive committee and various other operating committees and share responsibilities for research and development using resources in their own infrastructures. With respect to SustivaErbitux*, Lilly manufactures bulk requirements for cetuximab in its own facilities and filling and finishing is performed by a third party for which BMS has oversight responsibility. BMS has exclusive distribution rights in North America and is responsible for promotional efforts in North America although Lilly has the percentageright to co-promote in the U.S. at their own expense. BMS is the principal in third-party customer sales in North America and pays Lilly a distribution fee for 39% of AtriplaErbitux* net sales in Europe recognizedNorth America plus a share of certain royalties paid by BMS is equalLilly. BMS’s rights and obligations with respect to the difference between the average net selling pricescommercialization of AtriplaErbitux* and Truvada* (emtricitabine and tenofovir disoproxil fumarate). This alliance will continue in Europe until either party terminates the arrangement or the last patent expiration occurs for Atripla*, Truvada* or Sustiva.North America expire in September 2018.

108



Pfizer
As described in the 2013 Form 10-K, BMS has an alliance with Pfizer relatingshared rights to EliquisErbitux* .in Japan under an agreement with Lilly and Merck KGaA and received 50% of the pre-tax profit from Merck KGaA’s net sales of Erbitux* in Japan which was further shared equally with Lilly. In December 2014, BMS received $60agreed to transfer its co-commercialization rights in Japan to Merck KGaA in May 2015 in exchange for future royalties through 2032 which will be included in other income when earned.

In April 2015, BMS agreed to transfer to Lilly rights to Erbitux* in North America in exchange for future royalties as described below. Rights include, but are not limited to, full commercialization and manufacturing operational responsibilities. The transaction is expected to be accounted for as a divestiture of a business upon completion of the transition and result in a non-cash charge of approximately $150 million of milestone payments from Pfizerto $200 million for intangible assets directly related to the acceptancebusiness and an allocation of goodwill.

Upon completion of the filingtransition, which is expected to occur in the U.S. forfourth quarter of 2015, BMS will begin to receive royalties through September 2018, which will be included in other income when earned. The royalty rates applicable to North America are 38% on Erbitux* sales up to $165 million in 2015, $650 million in 2016, $650 million in 2017 and $480 million in 2018, plus 20% on sales in excess of those amounts in each of the treatment of venous thromboembolism indication and the launch for the prevention of deep vein thrombosis in patients who have undergone hip or knee replacement surgery in the U.S.respective years.

The Medicines Company

As described in the 20132014 Form 10-K, BMS hashad an alliance with The Medicines Company for Recothrom on a global basis. In August 2014, The Medicines Company notified BMS that it will exerciseexercised its option to acquire the trademarks, intellectual property and inventory exclusively related tobusiness for $132 million, resulting in a gain of $59 million (including $35 million fair value of the product at a price (expected to be approximately $120 million) determined based on a multiple of sales plus the cost of inventory. The closing is expected to occuroption) in February 2015.

Valeant

As described in the 20132014 Form 10-K, BMS hashad an alliance with Valeant for certain mature brands in Europe. In March 2014, Valeant notified BMS that it will exerciseexercised its option to acquire the trademarks and intellectual property exclusively related to the products atbusiness for $61 million, resulting in a price (expected to be approximately $60 million) determined based on a multiplegain of sales. The closing is expected to occur in January 2015. A $16$88 million charge was included in other expense to increase the(including $34 million fair value of the option to $34 millionoption) in the first quarter of 2014.January 2015.

Reckitt Benckiser Group plc

As described in the 20132014 Form 10-K, BMS has an alliance with Reckitt Benckiser Group plc (Reckitt) covering certain BMS over-the-counter products sold primarily in Mexico and Brazil. Reckitt also has an option to acquire all remaining rights in such products for those markets and related inventories at the end of the alliance period (May 2016). In April 2014, the alliance was modified to provide an option to Reckitt to purchase thea BMS manufacturing facility located in Mexico primarily dedicated to the products included in the alliance. The options can only be exercised together. Substantially, all employees at the facility are expected to be transferred to Reckitt if the option is exercised. A $15During the three months ended March 31, 2015, a $36 million chargecredit was included in other expenseincome to increasedecrease the fair value of the option to $129$93 million indue to the second quarter of 2014.

Note 4. ACQUISITIONS

In April 2014, BMS acquired allstrengthening of the outstanding shares of iPierian, Inc. (iPierian), a biotechnology company focused on new treatments for tauopathies, a class of neurodegenerative diseases. The acquisition provides BMS with full rights to IPN007, a preclinical monoclonal antibody to treat progressive supranuclear palsy and other tauopathies. The consideration includes an upfront payment of $175 million, contingent development and regulatory milestone payments up to $550 million and future royalties on net sales if any of the acquired preclinical assets are approved and commercialized. No significant iPierian processes were acquired, therefore the transaction was accounted for as an asset acquisition because iPierian was determined not to be a "business" as that term is defined in ASC 805 - Business Combinations. The upfront payment allocated to IPN007 was $148 million and included in research and development expenses. The remaining $27 million was allocated to deferred tax assets for net operating losses and tax credit carryforwards.

11



Note 5. ASSETS HELD-FOR-SALE

As discussed in "Note 3. Alliances", BMS sold its diabetes business to AstraZeneca in February 2014 which previously comprised the global alliance with them. The diabetes business was treated as a single disposal group held-for-sale as of December 31, 2013. No write-down was required as the fair value of the business less costs to sell exceeded the related carrying value.

The following assets and liabilities of the diabetes business held-for-sale were presented separately from BMS’s other accounts:
Dollars in Millions December 31, 2013
Assets  
Receivables $83
Inventories 163
Deferred income taxes - current 125
Prepaid expenses and other 20
Property, plant and equipment 678
Goodwill 550
Other intangible assets 5,682
Other assets 119
Total assets held-for-sale 7,420
   
Liabilities  
Short-term borrowings and current portion of long-term debt 27
Accounts payable 30
Accrued expenses 148
Deferred income - current 352
Accrued rebates and returns 81
Deferred income - noncurrent 3,319
Deferred income taxes - noncurrent 946
Other liabilities 28
Total liabilities related to assets held-for-sale $4,931

Assets held-for-sale were $78 million at September 30, 2014, comprising of intangible assets and inventory to be transferred to The Medicines Company. See "—Note 3. Alliances" for further information.U.S. dollar against local currencies.

Note 64. OTHER (INCOME)/EXPENSE
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Interest expense$50
 $46
 $150
 $146
$51
 $54
Investment income(20) (23) (71) (76)(30) (23)
Provision for restructuring35
 6
 72
 212
12
 21
Litigation charges/(recoveries)10
 17
 19
 (5)
Litigation charges12
 29
Equity in net income of affiliates(12) (42) (81) (128)(26) (36)
Out-licensed intangible asset impairment18
 —
 18
 —
13
 —
Gain on sale of product lines, businesses and assets(315) —
 (567) (1)(154) (259)
Other alliance and licensing income(102) (31) (354) (120)(161) (108)
Pension curtailments, settlements and special termination benefits28
 37
 137
 138
27
 64
Other31
 (5) 88
 19
(43) 50
Other (income)/expense$(277) $5
 $(589) $185
$(299) $(208)

129



Note 75. RESTRUCTURING

The following is the provision for restructuring:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Employee termination benefits$34
 $4
 $68
 $205
$10
 $20
Other exit costs1
 2
 4
 7
2
 1
Provision for restructuring$35
 $6
 $72
 $212
$12
 $21

Restructuring charges included termination benefits for workforce reductions of manufacturing, selling, administrative, and research and development personnel across all geographic regions of approximately 360245 and 150180 for the three months ended September 30,March 31, 2015 and 2014, and 2013, respectively, and approximately 760 and 1,285 for the nine months ended September 30, 2014 and 2013, respectively. Employee termination benefits in the prior period were primarily attributable to sales force reductions following the restructuring of the Sanofi and Otsuka agreements. Employee termination costs in the aggregate range of $230 million to $280approximately $100 million are expected to be incurred in 2014 and 2015 primarily related to specialty care transformation initiatives designed to create a more simplified organization across all functions and geographic markets. Subject to local regulations, costs will not be recognized until completion of discussions with works councils.

The following table represents the activity of employee termination and other exit cost liabilities:
Dollars in Millions2014 20132015 2014
Liability at January 1$102
 $167
$156
 $102
Charges79
 223
12
 23
Changes in estimates(7) (11)—
 (2)
Provision for restructuring72
 212
12
 21
Foreign currency translation(1) 2
(11) 1
Spending(73) (191)
Liability at September 30$100
 $190
Payments(45) (27)
Liability at March 31$112
 $97

Note 86. INCOME TAXES

Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Earnings Before Income Taxes$1,008
 $818
 $2,441
 $2,022
$1,448
 $985
Provision for Income Taxes276
 126
 439
 177
249
 49
Effective tax rate27.4% 15.4% 18.0% 8.8%17.2% 5.0%

Changes in the effective tax rates between the current and prior period primarily resulted from the following items: 

Unfavorable earnings mix between high and low tax jurisdictions in 2014;
The first quarter of 2013 includes the retroactive reinstatement of the research and development tax credit and look through exception for the full year 2012 ($43 million). The applicable tax legislation for these items was not extended as of September 30, 2014, therefore the research and development tax credit was not considered in the 2014 effective tax rate;
All periods were impacted by other discrete tax benefits attributable to various charges as well as the quarterly tax impacts resulting from the sale of the diabetes business and the acquisition of iPierian in 2014. Minimal tax benefits were attributed to the sale of the diabetes business during the nine months ended September 30, 2014 resulting primarily from the capital loss deduction on the sale of the Amylin shares. No tax benefits were attributable to the research and development charge resulting from the acquisition of iPierian.


13



The effective tax rate is lower than the U.S. statutory rate of 35% primarily attributable tobecause of undistributed earnings of certain foreign subsidiaries that have been considered or are expected to be indefinitely reinvested offshore. These undistributed earnings primarily relate to operations in Ireland and Puerto Rico, which operate under favorable tax grants not scheduled to expire prior to 2023. If these undistributed earnings are repatriated to the U.S. in the future, or if it were determined that such earnings are to be remitted in the foreseeable future, additional tax provisions would be required. Reforms to U.S. tax laws related to foreign earnings have been proposed and if adopted, may increase taxes, which could reduce the results of operations and cash flows.

The current period includes a $57 million reduction of valuation allowances for U.S. capital loss carryforwards as a result of gains from business divestitures. The prior period includes a $96 million tax benefit attributed to the sale of the diabetes business primarily as a result of a capital loss deduction from the sale of the Amylin shares.

BMS is currently being audited by a number of tax authorities and significant disputes may arise related to issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. BMS estimates that it is reasonably possible that the total amount of unrecognized tax benefits at September 30, 2014March 31, 2015 could decrease in the range of approximately $320$310 million to $380$370 million in the next twelve months as a result of the settlement of certain tax audits and other events resulting in the payment of additional taxes, the adjustment of certain deferred taxes and/or the recognition of tax benefits. It is also reasonably possible that new issues will be raised by tax authorities which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction.

Effective January 2014, the Company adopted an update from the FASB that clarified existing guidance on the presentation of unrecognized tax benefits when various qualifying tax benefit carryforwards exist, including when the unrecognized tax benefit should be presented as a reduction to deferred tax assets or as a liability. As a result, non-current deferred tax assets and income tax liabilities were reduced by $236 million.

Note 9. EARNINGS PER SHARE
 Three Months Ended September 30, Nine Months Ended September 30,
Amounts in Millions, Except Per Share Data2014 2013 2014 2013
Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation$721
 $692
 $1,991
 $1,837
        
Weighted-average common shares outstanding – basic1,658
 1,646
 1,656
 1,643
Contingently convertible debt common stock equivalents1
 1
 1
 1
Incremental shares attributable to share-based compensation plans11
 15
 11
 15
Weighted-average common shares outstanding – diluted1,670
 1,662
 1,668
 1,659
        
Earnings per Common Share       
Basic$0.43
 $0.42
 $1.20
 $1.12
Diluted$0.43
 $0.42
 $1.19
 $1.11
        
Anti-dilutive weighted-average equivalent shares – stock incentive plans—
 —
 —
 —

1410



Note 107. EARNINGS PER SHARE
 Three Months Ended March 31,
Amounts in Millions, Except Per Share Data2015 2014
Net Earnings Attributable to BMS used for Basic and Diluted EPS Calculation$1,186
 $937
    
Weighted-average common shares outstanding – basic1,663
 1,652
Contingently convertible debt common stock equivalents—
 1
Incremental shares attributable to share-based compensation plans13
 13
Weighted-average common shares outstanding – diluted1,676
 1,666
    
Earnings per Common Share   
Basic$0.71
 $0.57
Diluted$0.71
 $0.56
    
Anti-dilutive weighted-average equivalent shares – stock incentive plans—
 —

Note 8. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
September 30, 2014 December 31, 2013March 31, 2015 December 31, 2014
Dollars in MillionsLevel 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 TotalLevel 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total
Cash and cash equivalents - Money market and other securities$—
 $4,356
 $—
 $4,356
 $—
 $3,201
 $—
 $3,201
$—
 $5,794
 $—
 $5,794
 $—
 $5,051
 $—
 $5,051
Marketable securities:                              
Certificates of deposit—
 1,163
 —
 1,163
 —
 122
 —
 122
—
 391
 —
 391
 —
 896
 —
 896
Commercial paper—
 250
 —
 250
 —
 —
 —
 —
Corporate debt securities—
 5,172
 —
 5,172
 —
 4,432
 —
 4,432
—
 5,081
 —
 5,081
 —
 5,259
 —
 5,259
Equity funds—
 91
 —
 91
 —
 74
 —
 74
—
 97
 —
 97
 —
 94
 —
 94
Fixed income funds—
 10
 —
 10
 —
 46
 —
 46
—
 11
 —
 11
 —
 11
 —
 11
Auction Rate Securities (ARS)—
 —
 12
 12
 —
 —
 12
 12
—
 —
 12
 12
 —
 —
 12
 12
Derivative assets:                              
Interest rate swap contracts—
 111
 —
 111
 —
 64
 —
 64
—
 38
 —
 38
 —
 46
 —
 46
Forward starting interest rate swap contracts—
 6
 —
 6
 —
 —
 —
 —
Foreign currency forward contracts—
 87
 —
 87
 —
 50
 —
 50
—
 142
 —
 142
 —
 118
 —
 118
Investments in equity of other companies18
 —
 —
 18
 —
 —
 —
 —
Equity investments32
 —
 —
 32
 36
 —
 —
 36
Derivative liabilities:                              
Interest rate swap contracts—
 (10) —
 (10) —
 (27) —
 (27)—
 —
 —
 —
 —
 (3) —
 (3)
Forward starting interest rate swap contracts—
 (35) —
 (35) —
 —
 —
 —
Foreign currency forward contracts—
 (2) —
 (2) —
 (35) —
 (35)—
 (4) —
 (4) —
 —
 —
 —
Written option liabilities(a)
—
 —
 (198) (198) —
 —
 (162) (162)
Contingent consideration liability(b)
—
 —
 (8) (8) —
 —
 (8) (8)
Written option liabilities—
 —
 (93) (93) —
 —
 (198) (198)
Contingent consideration liability—
 —
 (8) (8) —
 —
 (8) (8)

(a)Includes $69 million and $18 million in accrued expenses and $129 million and $144 million in other liabilities as of September 30, 2014 and December 31, 2013, respectively.
(b)The contingent consideration liability is included in other liabilities.

As further described in "Note 10. Financial InstrumentInstruments and Fair Value Measurement"Measurements" in our 20132014 Form 10-K, our fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs), (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs) or (3) unobservable inputs (Level 3 inputs).


11



The following table summarizes the activity for financial assets and liabilities utilizing Level 3 fair value measurements:
2014 20132015 2014
Dollars in MillionsARS Contingent consideration liability Written option liabilities 
ARS and FRS(a)
 Contingent consideration liability Written option liabilitiesARS Written option liabilities Contingent consideration liability ARS Written option liabilities Contingent consideration liability
Fair value at January 1$12
 $(8) $(162) $31
 $(8) $(18)$12
 $(198) $(8) $12
 $(162) $(8)
Additions from new alliances—
 —
 —
 —
 —
 (144)
Sales—
 —
 —
 (20) —
 —
—
 69
 —
 —
 —
 —
Changes in fair value—
 —
 (36) —
 —
 —
—
 36
 —
 —
 (16) —
Fair value at September 30$12
 $(8) $(198) $11
 $(8) $(162)
Fair value at March 31$12
 $(93) $(8) $12
 $(178) $(8)

(a)FRS: Floating Rate Securities


15



Available-for-sale Securities

The following table summarizes available-for-sale securities:
 Dollars in MillionsAmortized
Cost		��Gross
Unrealized
Gain in
Accumulated
OCI		 Gross
Unrealized
Loss in
Accumulated
OCI		 Fair Value
 
 September 30, 2014       
 Certificates of deposit$1,163
 $—
 $—
 $1,163
 Commercial paper250
 —
 —
 250
 Corporate debt securities5,148
 33
 (9) 5,172
 ARS9
 3
 —
 12
 Investments in equity of other companies14
 4
 —
 18
 Total$6,584
 $40
 $(9) $6,615
         
 December 31, 2013       
 Certificates of deposit$122
 $—
 $—
 $122
 Corporate debt securities4,401
 44
 (13) 4,432
 ARS9
 3
 —
 12
 Total$4,532
 $47
 $(13) $4,566
 Dollars in MillionsAmortized
Cost		 Gross
Unrealized
Gain in
Accumulated
OCI		 Gross
Unrealized
Loss in
Accumulated
OCI		 Fair Value
 
 March 31, 2015       
 Certificates of deposit$391
 $—
 $—
 $391
 Corporate debt securities5,032
 51
 (2) 5,081
 ARS9
 3
 —
 12
 Equity investments14
 18
 —
 32
 Total$5,446
 $72
 $(2) $5,516
         
 December 31, 2014       
 Certificates of deposit$896
 $—
 $—
 $896
 Corporate debt securities5,237
 30
 (8) 5,259
 ARS9
 3
 —
 12
 Equity investments14
 22
 —
 36
 Total$6,156
 $55
 $(8) $6,203

Available-for-sale securities included in current marketable securities were $2,269$1,205 million as of September 30, 2014March 31, 2015 and $819$1,759 million as of December 31, 2013. Non-current2014. As of March 31, 2015, all non-current available-for-sale corporate debt securities maturingmature within five years, were $4,316 million asexcept for ARS. Equity investments of September 30, 2014. ARS maturing beyond 10 years were $12 million as of September 30, 2014. Investments in equity of other companies of $18$32 million are included in other assets as of September 30, 2014.March 31, 2015.

Fair Value Option for Financial Assets

The Company investsInvestments in equity and fixed income funds that are designed to offset theoffsetting changes in fair value of certain employee retirement benefits. Investments in equity and fixed income funds arebenefits were included in current marketable securities and were $91 million and $10 million, respectively, as of September 30, 2014 and $74 million and $46 million, respectively, as of December 31, 2013.securities. Investment income resulting from the change in fair value for the investments in equity and fixed income funds was not significant.

Qualifying Hedges
The following table summarizes the fair value of outstanding derivatives:
 September 30, 2014 December 31, 2013 March 31, 2015 December 31, 2014
Dollars in MillionsBalance Sheet Location Notional Fair Value Notional Fair ValueBalance Sheet Location Notional Fair Value Notional Fair Value
Derivatives designated as hedging instruments:                
Interest rate swap contractsOther assets $1,073
 $111
 $673
 $64
Other assets $1,250
 $38
 $847
 $46
Interest rate swap contractsOther liabilities 1,250
 (10) 1,950
 (27)Other liabilities 500
 —
 1,050
 (3)
Forward starting interest rate swap contractsOther assets 500
 6
 —
 —
Forward starting interest rate swap contractsOther liabilities 250
 (11) —
 —
Foreign currency forward contractsPrepaid expenses and other 1,012
 70
 301
 44
Prepaid expenses and other 904
 120
 1,323
 106
Foreign currency forward contractsOther assets 191
 17
 100
 6
Other assets 100
 22
 100
 12
Foreign currency forward contractsAccrued expenses 45
 (2) 704
 (31)Accrued expenses 500
 (4) —
 —
Foreign currency forward contractsOther liabilities —
 —
 263
 (4)

12



   March 31, 2015 December 31, 2014
Amounts in MillionsBalance Sheet Location Notional Fair Value Notional Fair Value
Derivatives designated as hedging instruments:         
Forward starting interest rate swap contractsAccrued expenses €500
 $(24) €—
 $—

Cash Flow Hedges — Foreign currency forward contracts are primarily utilized to hedge forecasted intercompany inventory purchase transactions in certain foreign currencies. These contracts are designated as cash flow hedges with the effective portion of changes in fair value being temporarily reported in accumulated other comprehensive loss and recognized in earnings when the hedged item affects earnings. The net gains on foreign currency forward contracts are expected to be reclassified to cost of products sold within the next two years. The notional amount of outstanding foreign currency forward contracts was primarily attributed to the Euroeuro ($490523 million) and the Japanese yen ($504724 million) at September 30, 2014.March 31, 2015. The fair value of a foreign currency forward contract attributed to the Japanese yen (notional amount of $130$375 million) not designated as a cash flow hedge was $8$(4) million and was included in prepaidaccrued expenses and other at September 30, 2014.March 31, 2015.


16BMS entered into several forward starting interest rate contracts to hedge the variability of probable forecasted interest expense. The contracts are designated as cash flow hedges with the effective portion of fair value changes included in other comprehensive income. €500 million notional amount of euro contracts mature in May 2015 and $750 million of U.S. contracts mature in March 2017.



The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not significant during the three months ended March 31, 2015 and 2014. Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring on the originally forecasted date, or 60 days thereafter, or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. Any ineffective portion of the change in fair value is included in current period earnings. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not significant during the nine months ended September 30, 2014 and 2013.

Net Investment Hedges — Non-U.S. dollar borrowings of €541 million ($690594 million) are designated to hedge the foreign currency exposures of the net investment in certain foreign affiliates. These borrowings are designated as net investment hedges and recognized in long-term debt. The effective portion of foreign exchange gains or losses on the remeasurement of the debt is recognized in the foreign currency translation component of accumulated other comprehensive loss with the related offset in long-term debt.

Fair Value Hedges — Fixed-to-floating interest rate swap contracts are designated as fair value hedges and are used as part of an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The swaps and underlying debt for the benchmark risk being hedged are recorded at fair value. When the underlying swap is terminated prior to maturity, the fair value basis adjustment to the underlying debt instrument is amortized into earnings as an adjustment to interest expense over the remaining term of the debt.

Fixed-to-floatingThe notional amount of fixed-to-floating interest rate swap contracts were executedterminated in 2014 to convert $2002015 was $147 million, notional amount from fixed rate to variable rate debt. generating proceeds of $28 million (including accrued interest of $1 million).

Long-term debt and the current portion of long-term debt includes:
Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Principal Value$6,870
 $7,593
$6,677
 $6,804
Adjustments to Principal Value:      
Fair value of interest rate swap contracts101
 37
38
 43
Unamortized basis adjustment from interest rate swap contract terminations356
 442
470
 454
Unamortized bond discounts(60) (64)(58) (59)
Total$7,267
 $8,008
$7,127
 $7,242
   
Current portion of long-term debt(a)
$—
 $27
Long-term debt7,267
 7,981

(a)Included in liabilities related to assets held-for-sale at December 31, 2013.

The fair value of debt was $7,924$8,065 million at September 30, 2014March 31, 2015 and $8,487$8,045 million at December 31, 20132014 and was valued using Level 2 inputs. Interest payments were $131$34 million and $158$37 million for the ninethree months ended September 30, 2014March 31, 2015 and 20132014, respectively, net of amounts related to interest rate swap contracts.

No commercial paper borrowings were outstanding as of September 30, 2014 and December 31, 2013.

The following information pertains to the outstanding 5.45% Notes due 2018 that were redeemed in February 2014:
 Nine Months Ended
Dollars in MillionsSeptember 30, 2014
Principal amount$582
Carrying value633
Debt redemption price676
Notional amount of interest rate swap contracts terminated500
Interest rate swap contract termination payments(4)
Total loss45

1713



There were no debt redemptions in 2015, see below for the debt redemption in 2014:
 Three Months Ended
Dollars in MillionsMarch 31, 2014
Principal amount$582
Carrying value633
Debt redemption price676
Notional amount of interest rate swap contracts terminated500
Interest rate swap contract termination payments(4)
Total loss45

Note 119. RECEIVABLES

Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Trade receivables$1,911
 $1,779
$2,338
 $2,193
Less allowances(88) (89)(88) (93)
Net trade receivables1,823
 1,690
2,250
 2,100
Alliance partners receivables1,061
 1,122
956
 888
Prepaid and refundable income taxes144
 262
118
 178
Other293
 286
134
 224
Receivables$3,321
 $3,360
$3,458
 $3,390

Non-U.S. receivables sold on a nonrecourse basis were $684$93 million and $728215 million for the ninethree months ended September 30, 2014March 31, 2015 and 20132014, respectively. In the aggregate, receivables due from our three largest pharmaceutical wholesalers in the U.S. represented 38%33% and 40%36% of total trade receivables at September 30, 2014March 31, 2015 and December 31, 20132014, respectively.

Note 1210. INVENTORIES

Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Finished goods$449
 $491
$473
 $500
Work in process787
 757
689
 856
Raw and packaging materials329
 250
275
 204
Inventories$1,565
 $1,498
$1,437
 $1,560

Inventories expected to remain on-hand beyond one year are included in other assets and were $271$241 million at September 30, 2014March 31, 2015 and $351232 million at December 31, 20132014.

Note 1311. PROPERTY, PLANT AND EQUIPMENT

Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Land$109
 $109
$108
 $109
Buildings4,784
 4,748
4,806
 4,830
Machinery, equipment and fixtures3,747
 3,699
3,693
 3,774
Construction in progress322
 287
383
 353
Gross property, plant and equipment8,962
 8,843
8,990
 9,066
Less accumulated depreciation(4,575) (4,264)(4,667) (4,649)
Property, plant and equipment$4,387
 $4,579
$4,323
 $4,417

The Mount Vernon, Indiana manufacturing facility's carrying value was approximately $256$200 million as of September 30, 2014.March 31, 2015. The facility is expected to be sold in the third quarter of 2015. It was not included in assets held-for-sale for both periods because the assets were not available for immediate sale in their present condition. See "Note 3. Alliances” for further discussion on the sale of the diabetes business.

Depreciation expense was $412$133 million and $333138 million for the ninethree months ended September 30, 2014March 31, 2015 and 20132014, respectively.

14



Note 14.12. OTHER INTANGIBLE ASSETS

Dollars in MillionsSeptember 30,
2014		 December 31,
2013
Licenses$1,126
 $1,162
Developed technology rights2,358
 2,486
Capitalized software1,265
 1,240
In-process research and development (IPRD)205
 548
Gross other intangible assets4,954
 5,436
Less accumulated amortization(3,236) (3,118)
Total other intangible assets$1,718
 $2,318

18




A $310 million IPRD impairment charge was recognized in the second quarter of 2014 for peginterferon lambda which was in Phase III development for treatment of hepatitis C virus. The full write-off was required after assessing the potential commercial viability of the asset and estimating its fair value. The assessment considered the lower likelihood of filing for registration in certain markets after completing revised projections of revenues and expenses. A significant decline from prior projected revenues resulted from the global introduction of oral non-interferon products being used to treat patients with hepatitis C virus and no other alternative uses for the product.
Dollars in MillionsMarch 31,
2015		 December 31,
2014
Licenses$1,074
 $1,090
Developed technology rights2,357
 2,358
Capitalized software1,270
 1,254
In-process research and development (IPRD)280
 280
Gross other intangible assets4,981
 4,982
Less accumulated amortization(3,275) (3,229)
Total other intangible assets$1,706
 $1,753

Amortization expense was $222$52 million and $647$79 million for the ninethree months ended September 30,March 31, 2015 and 2014, and 2013, respectively.

Note 1513. DEFERRED INCOME
Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Alliances (Note 3)$1,515
 $1,418
$1,647
 $1,493
Gain on sale-leaseback transactions50
 71
39
 45
Other240
 36
470
 399
Total deferred income$1,805
 $1,525
$2,156
 $1,937
      
Current portion$995
 $756
$1,459
 $1,167
Non-current portion810
 769
697
 770

Alliances include unamortized amounts for upfront, milestone and other licensing receipts, revenue deferrals attributed to the Gilead alliance and deferred income for the undelivered elements of the diabetes business divestiture. Other deferrals include approximately $200 millionamounts invoiced for a product under an early access program in the EU that is subject to final price negotiations with the local government.government (approximately$350 million at March 31, 2015 and $300 million at December 31, 2014).
Amortization of deferred income was $270$81 million and $39880 million for the ninethree months ended September 30, 2014March 31, 2015 and 20132014, respectively.

Note 1614. EQUITY

Common Stock 
Capital in  Excess
of Par Value
of Stock
 
Retained
Earnings
 Treasury Stock 
Noncontrolling
Interest
Common Stock 
Capital in  Excess
of Par Value
of Stock
 
Retained
Earnings
 Treasury Stock 
Noncontrolling
Interest
Dollars and Shares in MillionsShares Par Value Shares Cost Shares Par Value Shares Cost 
Balance at January 1, 20132,208
 $221
 $2,694
 $32,733
 570
 $(18,823) $15
Net earnings—
 —
 —
 1,837
 —
 —
 19
Cash dividends declared—
 —
 —
 (1,744) —
 —
 —
Stock repurchase program—
 —
 —
 —
 11
 (413) —
Employee stock compensation plans—
 —
 (728) —
 (20) 1,261
 —
Distributions—
 —
 —
 —
 —
 —
 (46)
Balance at September 30, 20132,208
 $221
 $1,966
 $32,826
 561
 $(17,975) $(12)
             
Balance at January 1, 20142,208
 $221
 $1,922
 $32,952
 559
 $(17,800) $82
2,208
 $221
 $1,922
 $32,952
 559
 $(17,800) $82
Net earnings—
 —
 —
 1,991
 —
 —
 11
—
 —
 —
 937
 —
 —
 (1)
Cash dividends declared—
 —
 —
 (1,796) —
 —
 —
—
 —
 —
 (598) —
 —
 —
Employee stock compensation plans—
 —
 (407) —
 (9) 646
 —
—
 —
 (457) —
 (7) 544
 —
Debt conversion—
 —
 (16) —
 (1) 35
 —
—
 —
 (16) —
 (1) 35
 —
Distributions—
 —
 —
 —
 —
 —
 (35)—
 —
 —
 —
 —
 —
 (23)
Balance at September 30, 20142,208
 $221
 $1,499
 $33,147
 549
 $(17,119) $58
Balance at March 31, 20142,208
 $221
 $1,449
 $33,291
 551
 $(17,221) $58
             
Balance at January 1, 20152,208
 $221
 $1,507
 $32,541
 547
 $(16,992) $131
Net earnings—
 —
 —
 1,186
 —
 —
 15
Cash dividends declared—
 —
 —
 (617) —
 —
 —
Employee stock compensation plans—
 —
 (193) —
 (6) 309
 —
Distributions—
 —
 —
 —
 —
 —
 (3)
Balance at March 31, 20152,208
 $221
 $1,314
 $33,110
 541
 $(16,683) $143


1915



The components of other comprehensive income/(loss) were as follows:
2014 20132015 2014
Pretax Tax After tax Pretax Tax After taxPretax Tax After tax Pretax Tax After tax
Three Months Ended September 30,           
Three Months Ended March 31,           
Derivatives qualifying as cash flow hedges:(a)
                      
Unrealized gains/(losses)$96
 $(31) $65
 $(39) $10
 $(29)$35
 $(11) $24
 $(5) $2
 $(3)
Reclassified to net earnings(13) 5
 (8) (3) 1
 (2)(27) 9
 (18) (2) 2
 —
Derivatives qualifying as cash flow hedges83
 (26) 57
 (42) 11
 (31)8
 (2) 6
 (7) 4
 (3)
Pension and postretirement benefits:                      
Actuarial gains/(losses)(679) 236
 (443) 269
 (81) 188
Amortization(b)
26
 (8) 18
 29
 (11) 18
Settlements(c)
28
 (10) 18
 37
 (11) 26
Pension and postretirement benefits(625) 218
 (407) 335
 (103) 232
Available for sale securities:           
Unrealized gains/(losses)(35) 13
 (22) 19
 (5) 14
Realized gains—
 —
 —
 —
 —
 —
Available for sale securities(35) 13
 (22) 19
 (5) 14
Foreign currency translation(8) —
 (8) (7) —
 (7)
$(585) $205
 $(380) $305
 $(97) $208
           
Nine Months Ended September 30,           
Derivatives qualifying as cash flow hedges:(a)
           
Unrealized gains$77
 $(25) $52
 $60
 $(23) $37
Reclassified to net earnings(8) 5
 (3) (47) 17
 (30)
Derivatives qualifying as cash flow hedges69
 (20) 49
 13
 (6) 7
Pension and postretirement benefits:           
Actuarial gains/(losses)(978) 339
 (639) 1,204
 (411) 793
Actuarial losses(120) 42
 (78) (250) 90
 (160)
Amortization(b)
79
 (27) 52
 105
 (34) 71
23
 (6) 17
 26
 (13) 13
Curtailments and settlements(c)
127
 (48) 79
 138
 (46) 92
27
 (10) 17
 54
 (21) 33
Pension and postretirement benefits(772) 264
 (508) 1,447
 (491) 956
(70) 26
 (44) (170) 56
 (114)
Available for sale securities:           
Unrealized losses(6) —
 (6) (32) 5
 (27)
Available-for-sale securities:           
Unrealized gains25
 (8) 17
 4
 (2) 2
Realized gains(1) —
 (1) (8) 3
 (5)(1) —
 (1) —
 —
 —
Available for sale securities(7) —
 (7) (40) 8
 (32)
Available-for-sale securities24
 (8) 16
 4
 (2) 2
Foreign currency translation2
 —
 2
 (41) —
 (41)46
 (15) 31
 (11) —
 (11)
$(708) $244
 $(464) $1,379
 $(489) $890
$8
 $1
 $9
 $(184) $58
 $(126)

(a)Reclassifications to net earnings of derivatives qualifying as effective hedges are recognized in cost of products sold.
(b)Actuarial lossesgains/(losses) and prior service cost are amortized into cost of products sold, research and development, and marketing, selling and administrative expenses as appropriate.
(c)Pension curtailments and settlements are recognized in other (income)/expense.

The accumulated balances related to each component of other comprehensive loss, net of taxes, were as follows:
Dollars in MillionsSeptember 30,
2014		 December 31, 2013March 31,
2015		 December 31, 2014
Derivatives qualifying as cash flow hedges$65
 $16
$91
 $85
Pension and other postretirement benefits(2,365) (1,857)(2,225) (2,181)
Available for sale securities21
 28
Available-for-sale securities47
 31
Foreign currency translation(326) (328)(329) (360)
Accumulated other comprehensive loss$(2,605) $(2,141)$(2,416) $(2,425)

20



Note 1715. PENSION AND POSTRETIREMENT BENEFIT PLANS

The net periodic benefit cost/(credit) of defined benefit pension and postretirement benefit plans includes:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Pension Benefits Other Benefits Pension Benefits Other BenefitsPension Benefits Other Benefits
Dollars in Millions2014 2013 2014 2013 2014 2013 2014 20132015 2014 2015 2014
Service cost – benefits earned during the year$10
 $10
 $1
 $1
 $30
 $29
 $3
 $4
$6
 $10
 $1
 $1
Interest cost on projected benefit obligation76
 76
 3
 3
 231
 225
 10
 10
61
 78
 3
 3
Expected return on plan assets(131) (128) (7) (7) (395) (391) (21) (20)(102) (131) (7) (7)
Amortization of prior service credits(1) (1) —
 —
 (3) (3) (1) (1)(1) (1) (1) —
Amortization of net actuarial (gain)/loss29
 30
 (2) —
 85
 105
 (2) —
Amortization of net actuarial loss24
 27
 1
 —
Curtailments and settlements28
 37
 —
 —
 127
 138
 (3) —
27
 54
 —
 (3)
Special termination benefits—
 —
 —
 —
 13
 —
 —
 —
—
 13
 —
 —
Net periodic cost/(credit)$11
 $24
 $(5) $(3) $88
 $103
 $(14) $(7)$15
 $50
 $(3) $(6)

Pension settlement charges were recognized after determining that the annual lump sum payments will likely exceed the annual interest and service costs for certain pension plans, including the primary U.S. pension plan. The charges included the acceleration of a portion of unrecognized actuarial losses. The applicable pension benefit obligation and pension plan assets were remeasured during 20142015 resulting in a decreasean increase to other assetsliabilities and a corresponding increase in accumulated other comprehensive loss of $978$120 million. The changes resulted from revised mortality rates and a lower weighted average discount rate assumed in remeasuring the pension benefit obligations (4.1%(3.6% at September 30, 2014March 31, 2015 and 4.6%3.8% at December 31, 2013)2014) partially offset by higher actual return on plan assets than expected. Contributions to the pension plans are expected to approximate $120$100 million during 2014,2015, of which $100$40 million were incurredoccurred in the ninethree months ended September 30, 2014.March 31, 2015.


16



The expense attributed to defined contribution plans in the U.S. was $45$44 million and $50 million for the three months ended September 30,March 31, 2015, and 2014, and 2013, respectively, and $141 million and $140 million for the nine months ended September 30, 2014, and 2013, respectively.

On September 29, 2014, BMS and Fiduciary Counselors Inc., as an independent fiduciary of the Bristol-Myers Squibb Company Retirement Income Plan, entered into a definitive agreement to transfer certain U.S. pension assets to The Prudential Insurance Company of America (Prudential) to settle approximately $1.4 billion of pension obligations. Pursuant to the agreement, BMS will purchase a group annuity contract from Prudential, which will then irrevocably assume the obligation to make future annuity payments to certain BMS retirees. The transaction will not change the amount of the monthly pension benefit received by affected retirees and surviving  beneficiaries or any rights to future payments that are currently offered by the plan. The transaction is expected to close during the fourth quarter of 2014 subject to certain closing conditions and result in a pre-tax settlement charge of approximately $600 million to $700 million subject to final valuations at the date of closing.

Note 1816. EMPLOYEE STOCK BENEFIT PLANS

Stock-based compensation expense was as follows:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Stock options$—
 $—
 $—
 $1
Restricted stock18
 19
 56
 56
$21
 $19
Market share units9
 5
 25
 21
9
 9
Performance share units21
 21
 66
 62
24
 21
Total stock-based compensation expense$48
 $45
 $147
 $140
$54
 $49
          
Income tax benefit$16
 $13
 $49
 $47
$18
 $16

In the ninethree months ended September 30, 2014, 1.8March 31, 2015, 1.6 million restricted stock units, 0.90.7 million market share units and 2.31.5 million performance share units were granted. The weighted-average grant date fair value was $52.14$61.26 for restricted stock units, $55.44$67.17 for market share units and $55.17$65.09 for performance share units granted during the ninethree months ended September 30, 2014.March 31, 2015.

Substantially all restricted stock units vest ratably over a four year period. Market share units vest ratably over a four year period and the number of shares ultimately issued is based on share price performance. The fair value of market share units considers the probability of satisfying market conditions. Performance share units vest at the end of the three-year performance period. The number of shares issued when performance share units vest is determined based on the achievement of annual performance goals. The number of shares issued for 2014-2016 and 2015-2017 performance share unit awards are also adjusted based on the Company's three-year total shareholder return relative to a peer group of companies. Performance share units vest at the end of the three -year performance period.

Unrecognized compensation cost related to nonvested awards of $310$463 million is expected to be recognized over a weighted-average period of 2.52.7 years.

21




Note 1917. LEGAL PROCEEDINGS AND CONTINGENCIES
The Company and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. The Company recognizes accruals for such contingencies when it is probable that a liability will be incurred and the amount of loss can be reasonably estimated. These matters involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage. Legal proceedings that are material or that the Company believes could become material are described below.

Although the Company believes it has substantial defenses in these matters, there can be no assurance that there will not be an increase in the scope of pending matters or that any future lawsuits, claims, government investigations or other legal proceedings will not be material. Unless otherwise noted, the Company is unable to assess the outcome of the respective litigation nor is it able to provide an estimated range of potential loss. Furthermore, failure to enforce our patent rights would likely result in substantial decreases in the respective product revenues from generic competition.
INTELLECTUAL PROPERTY
Atripla*
In April 2009, Teva Pharmaceutical Industries Ltd. (Teva) filed an abbreviated New Drug Application (aNDA) to manufacture and market a generic version of Atripla*. Atripla* is a single tablet three-drug regimen combining the Company’s Sustiva (efavirenz) and Gilead’s Truvada* (emtricitabine and tenofovir disproxil fumarate). As of this time, the Company’s U.S. patent rights covering Sustiva’s method of use has not been challenged. The composition of matter expired in November 2013. Teva sent Gilead a Paragraph IV certification letter challenging two of the fifteen Orange Book-listed patents for Atripla*. In May 2009, Gilead filed a patent infringement action against Teva in the U.S. District Court for the Southern District of New York (SDNY). In January 2010, the Company received a notice that Teva amended its aNDA and was challenging eight additional Orange Book-listed patents for Atripla*. In March 2010, the Company and Merck, Sharp & Dohme Corp. (Merck) filed a patent infringement action against Teva also in the SDNY relating to two U.S. patents which claim crystalline or polymorph forms of efavirenz. In August 2013, the Company, Merck and Teva reached a settlement relating to the two efavirenz polymorph patents and the case has been dismissed. In March 2010, Gilead filed two patent infringement actions against Teva in the SDNY relating to six Orange Book-listed patents for Atripla* and in April 2013, Gilead and Teva reached an agreement to settle the lawsuit on the patents covering tenofovir disoproxil fumarate. In April 2014, Gilead and Teva entered an agreement to settle the ongoing litigation concerning the emtricitabine patents covering Atripla* and Truvada*.
Baraclude
In August 2010, Teva filed an aNDA to manufacture and market generic versions of Baraclude. The Company received a Paragraph IV certification letter from Teva challenging the one Orange Book-listed patent for Baraclude, U.S. Patent No. 5,206,244 (the ‘244 Patent), covering the entecavir molecule. In September 2010, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware (Delaware District Court) against Teva for infringement. In February 2013, the Delaware District Court ruled against the Company and invalidated the ‘244 Patent. The Company has appealed the Delaware District Court’s decision and in June 2014 the U.S. Court of Appeals for the Federal Circuit (Federal Court of Appeals) denied the Company's appeal. In July 2014, the Company filed a petition for an en banc rehearing by the entire Federal Court of Appeals which was denied in October 2014. TheIn January 2015, the Company is evaluating all its legal options.filed a petition for a writ of certiorari with the U.S. Supreme Court requesting that the court hear an appeal of the Federal Court of Appeals decision. In September 2014, Teva received final approval from the FDA for its generic version of entecavir and launched its product in the U.S. We expecthave experienced a rapid and significant negative impact on U.S. net product sales of Baraclude beginning in the fourth quarter of 2014. U.S. net product sales of Baraclude were $289$215 million in 2013.2014.

17



Baraclude — South Korea

In 2013, Daewoong Pharmaceutical Co. Ltd. and, Hanmi Pharmaceuticals Co., Ltd. and other generic companies initiated separate invalidity actions in the Korean Intellectual Property Office (KIPO) against Korean Patent No. 160,523 (the ‘523 patent).  The ‘523 patent expires in October 2015 and is the Korean equivalent of the ‘244 Patent, the U.S. composition of matter patent. The invalidity actions have been consolidated and are pending. We are likely to receive a decision in 2014.In January 2015, the Korean Intellectual Property Tribunal ruled that the '523 patent is valid. In February 2015, an appeal of this ruling was filed by certain generic companies.  There isstill remains a risk that generic companies maycould launch generic versions of Baraclude prior to October 2015. Net product sales of Baraclude in South Korea were $158 million in 2013.2014.

22



Plavix* — Australia
As previously disclosed, Sanofi was notified that, in August 2007, GenRx Proprietary Limited (GenRx) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc. (Apotex), has since changed its name to Apotex. In August 2007, Apotex filed an application in the Federal Court of Australia (the Federal Court) seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court granted Sanofi’s injunction. A subsidiary of the Company was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the Apotex case and a trial occurred in April 2008. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. The Company and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (Full Court) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims which have stayed the Federal Court’s ruling. Apotex filed a notice of appeal appealing the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. A hearing on the appeals occurred in February 2009. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In November 2009, the Company and Sanofi applied to the High Court of Australia (High Court) for special leave to appeal the judgment of the Full Court. In March 2010, the High Court denied the Company and Sanofi’s request to hear the appeal of the Full Court decision. The case has been remanded to the Federal Court for further proceedings related to damages sought by Apotex.  The Australian government has intervened in this matter and is also seeking damages for alleged losses experienced during the period when the injunction was in place. The Company and Apotex have settled the Apotex case and the case has been dismissed. The Australian government's claim is still pending. It is not possible at this time to predict the outcome of the Australian government’s claim or its impact on the Company.

Plavix* — Canada (Apotex, Inc.)
On April 22, 2009, Apotex filed an impeachment action against Sanofi in the Federal Court of Canada alleging that Sanofi’s Canadian Patent No. 1,336,777 (the ‘777 Patent) is invalid. On June 8, 2009, Sanofi filed its defense to the impeachment action and filed a suit against Apotex for infringement of the ‘777 Patent. The trial was completed in June 2011 and in December 2011, the Federal Court of Canada issued a decision that the ‘777 Patent is invalid. In July 2013, the Federal Court of Appeal reversed the Federal Court of Canada's decision and upheld the validity of the '777 Patent. The case was remanded to the Federal Court of Canada to consider the damages owed to the Company by Apotex for the infringement of the ‘777 patent. In September 2013, Apotex sought leave to appeal the decision of the Federal Court of Appeal to the Supreme Court of Canada and the Supreme Court of Canada is scheduled to hear the case in November 2014.
GENERAL COMMERCIAL LITIGATION
Remaining Apotex Matter Related toPlavix*
As previously disclosed, in January 2011, Apotex filed a lawsuit in Florida State Court, Broward County, alleging breach of contract relating to the May 2006 proposed settlement agreement with Apotex relating to the then pending Plavix* patent litigation. A trial was held in March 2013 and a jury verdict was delivered in favor of the Company. Apotex has appealed this decision.
PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION AND INVESTIGATIONS
Abilify*Federal Subpoena
In January 2012, the Company received a subpoena from the United States Attorney’s Office for the SDNY requesting information related to, among other things, the sales and marketing of Abilify*. It is not possible at this time to assess the outcome of this matter or its potential impact on the Company.
Abilify* State Attorneys General Investigation
In March 2009, the Company received a letter from the Delaware Attorney General’s Office advising of a multi-state coalition investigating whether certain Abilify* marketing practices violated those respective states’ consumer protection statutes. The Company has entered into a tolling agreement with the states. It is not possible at this time to reasonably assess the outcome of this investigation.
AWP Litigation
As previously disclosed, the Company, together with a number of other pharmaceutical manufacturers, has been a defendant in a number of private class actions as well as suits brought by the attorneys general of various states. In these actions, plaintiffs allege that defendants caused the Average Wholesale Prices (AWPs) of their products to be inflated, thereby injuring government programs, entities and persons who reimbursed prescription drugs based on AWPs. The Company remains a defendant in two state attorneys general suits pending in state courts in Pennsylvania and Wisconsin. Beginning in August 2010, the Company was the defendant in a trial in the Commonwealth Court of Pennsylvania (Commonwealth Court), brought by the Commonwealth of Pennsylvania. In September 2010, the jury issued a

23



verdict for the Company, finding that the Company was not liable for fraudulent or negligent misrepresentation; however, the Commonwealth Court judge issued a decision on a Pennsylvania consumer protection claim that did not go to the jury, finding the Company liable for $28$28 million and enjoining the Company from contributing to the provision of inflated AWPs. The Company appealed the decision to the Pennsylvania Supreme Court and oral argument took place in May 2013. In June 2014, the Pennsylvania Supreme Court vacated the Commonwealth judge's decision and remanded the matter back to the Commonwealth Court. In January 2015, the Commonwealth Court entered judgment in favor of the Company. The Commonwealth of Pennsylvania has appealed this decision to the Pennsylvania Supreme Court.
Qui Tam Litigation
In March 2011, the Company was served with an unsealed qui tam complaint filed by three former sales representatives in California Superior Court, County of Los Angeles. The California Department of Insurance has elected to intervene in the lawsuit. The complaint alleges the Company paid kickbacks to California providers and pharmacies in violation of California Insurance Frauds Prevention Act, Cal. Ins. Code § 1871.7. It is not possible at this time to reasonably assess the outcome of this lawsuit or its impact on the Company.

18



Plavix* State Attorneys General Lawsuits
The Company and certain affiliates of Sanofi are defendants in consumer protection and/or false advertising actions brought by several states relating to the sales and promotion of Plavix*. It is not possible at this time to reasonably assess the outcome of these lawsuits or their potential impact on the Company.
PRODUCT LIABILITY LITIGATION
The Company is a party to various product liability lawsuits. As previously disclosed, in addition to lawsuits, the Company also faces unfiled claims involving its products.
Plavix*
As previously disclosed, the Company and certain affiliates of Sanofi are defendants in a number of individual lawsuits in various state and federal courts claiming personal injury damage allegedly sustained after using Plavix*. Currently, over 6,3005,600 claims involving injury plaintiffs as well as claims by spouses and/or other beneficiaries, are filed in state and federal courts in various states including California, Illinois, New Jersey, Delaware and New York. In February 2013, the Judicial Panel on Multidistrict Litigation granted the Company and Sanofi’s motion to establish a multidistrict litigation to coordinate Federal pretrial proceedings in Plavix* product liability and related cases in New Jersey Federal Court. It is not possible at this time to reasonably assess the outcome of these lawsuits or the potential impact on the Company.
Reglan*
The Company is one of a number of defendants in numerous lawsuits, on behalf of approximately 3,000 plaintiffs, including injury plaintiffs claiming personal injury allegedly sustained after using Reglan* or another brand of the generic drug metoclopramide, a product indicated for gastroesophageal reflux and certain other gastrointestinal disorders, as well as claims by spouses and/or other beneficiaries. The Company, through its generic subsidiary, Apothecon, Inc., distributed metoclopramide tablets manufactured by another party between 1996 and 2000. It is not possible at this time to reasonably assess the outcome of these lawsuits. The resolution of these pending lawsuits, however, is not expected to have a material impact on the Company.
Byetta*
Amylin, a former subsidiary of the Company, and Lilly are co-defendants in product liability litigation related to Byetta*.. To date, there are over 400460 separate lawsuits pending on behalf of over 1,9002,200 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The Company has agreed in principle to resolve over 510 of these claims. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta*, primarily pancreatic cancer and pancreatitis, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in Federal Court in San Diego in a recently established multidistrict litigation, with the next largest contingent of cases pending in a coordinated proceeding in California Superior Court in Los Angeles. Amylin has product liability insurance covering a substantial number of claims involving Byetta* and any additional liability to Amylin with respect to Byetta*is expected to be shared between the Company and AstraZeneca. It is not possible to reasonably predict the outcome of any lawsuit, claim or proceeding or the potential impact on the Company.
ENVIRONMENTAL PROCEEDINGS
As previously reported, the Company is a party to several environmental proceedings and other matters, and is responsible under various state, federal and foreign laws, including the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA), for certain costs of investigating and/or remediating contamination resulting from past industrial activity at the Company’s current or former sites or at waste disposal or reprocessing facilities operated by third-parties.third parties.

24



CERCLA Matters
With respect to CERCLA matters for which the Company is responsible under various state, federal and foreign laws, the Company typically estimates potential costs based on information obtained from the U.S. Environmental Protection Agency, or counterpart state or foreign agency and/or studies prepared by independent consultants, including the total estimated costs for the site and the expected cost-sharing, if any, with other “potentially responsible parties,” and the Company accrues liabilities when they are probable and reasonably estimable. The Company estimated its share of future costs for these sites to be $63$61 million at September 30, 2014,March 31, 2015, which represents the sum of best estimates or, where no best estimate can reasonably be made, estimates of the minimal probable amount among a range of such costs (without taking into account any potential recoveries from other parties).

19
New Brunswick Facility—Environmental & Personal Injury Lawsuits
Since May 2008, over 300 lawsuits have been filed against the Company in New Jersey Superior Court by or on behalf of current and former residents of New Brunswick, New Jersey who live or have lived adjacent to the Company’s New Brunswick facility. The complaints allege various personal injuries resulting from environmental contamination at the New Brunswick facility and historical operations at that site, or are claims for medical monitoring. A portion of these complaints also assert claims for alleged property damage. In October 2008, the New Jersey Supreme Court granted Mass Tort status to these cases and transferred them to the New Jersey Superior Court in Atlantic County for centralized case management purposes. Since October 2011, over 200 additional cases have been filed in New Jersey Superior Court and removed by the Company to United States District Court, District of New Jersey. Accordingly, there are in excess of 500 cases between the state and federal court actions. In June 2014, the Company and the plaintiffs agreed to a settlement, subject to finalization.


North Brunswick Township Board of Education
As previously disclosed, in October 2003, the Company was contacted by counsel representing the North Brunswick, NJ Board of Education (BOE) regarding a site where waste materials from E.R. Squibb and Sons may have been disposed from the 1940’s through the 1960’s. Fill material containing industrial waste and heavy metals in excess of residential standards was discovered during an expansion project at the North Brunswick Township High School, as well as at a number of neighboring residential properties and adjacent public park areas. In January 2004, the New Jersey Department of Environmental Protection (NJDEP) sent the Company and others an information request letter about possible waste disposal at the site, to which the Company responded in March 2004. The BOE and the Township, as the current owners of the school property and the park, are conducting and jointly financing soil remediation work and ground water investigation work under a work plan approved by the NJDEP, and have asked the Company to contribute to the cost. The Company is actively monitoring the clean-up project, including its costs. To date, neither the school board nor the Township has asserted any claim against the Company. Instead, the Company and the local entities have negotiated an agreement to attempt to resolve the matter by informal means, and avoid litigation. A central component of the agreement is the provision by the Company of interim funding to help defray cleanup costs and assure the work is not interrupted. The Company transmitted interim funding payments in December 2007 and November 2009. The parties commenced mediation in late 2008; however, those efforts were not successful and the parties moved to a binding allocation process. The parties are expected to conduct fact and expert discovery, followed by formal evidentiary hearings and written argument. Hearings are scheduled to commence in March 2015. In addition, in September 2009, the Township and BOE filed suits against several other parties alleged to have contributed waste materials to the site; that litigation has now been settled by the parties. The Company does not currently believe that it is responsible for any additional amounts beyond the two interim payments totaling $4$4 million already transmitted. Any additional possible loss is not expected to be material.
OTHER PROCEEDINGS
SEC Germany Investigation
In October 2006, the SEC informed the Company that it had begun a formal inquiry into the activities of certain of the Company’s German pharmaceutical subsidiaries and its employees and/or agents.  The SEC’s inquiry encompasses matters formerly under investigation by the German prosecutor in Munich, Germany, which have since been resolved. The Company understands the inquiry concerns potential violations of the Foreign Corrupt Practices Act (FCPA). The Company has been cooperating with the SEC.
FCPA Investigation
In March 2012, the Company received a subpoena from the SEC issued in connection with its investigation under the FCPA, primarily relating to sales and marketing practices in various countries. The Company is cooperating with the SEC, along with the Department of Justice, in its investigation of these matters. In particular, the Company is investigating certain sales and marketing practices in China. The Company has been cooperating with the government in its investigation and is currently in discussions regarding the potential resolution of these matters. It is not possible at this time to assesspredict the outcome of these matters or their potential impactdiscussions.

Note 18. SUBSEQUENT EVENTS

In April 2015, BMS acquired all of the outstanding shares of Flexus Biosciences, Inc. (Flexus), a privately held biotechnology company focused on the Company.

discovery and development of novel anti-cancer therapeutics. The acquisition provides BMS with full rights to F001287, a preclinical small molecule IDO1-inhibitor targeted immunotherapy with potential to be used in combination with BMS' immuno-oncology portfolio. In addition, the transaction included Flexus' IDO/TDO discovery program which includes its IDO-selective, IDO/TDO dual and TDO-selective compounds. The consideration includes an upfront payment of $800 million, and contingent development and regulatory milestone payments up to $450 million. The transaction is expected to be accounted for as an asset acquisition with essentially all value allocated to F001287 and the IDO/TDO discovery program which will be included in research and development expense.

2520



Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
EXECUTIVE SUMMARY
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us) is a global specialty biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We license, manufacture, market, distributecontinue to evolve our business to a leading diversified specialty biopharma company. This evolution was accelerated as a result of the diabetes business divestiture in 2014 and sell pharmaceutical productscontinued focus on certain therapeutic areas, including immuno-oncology. The following provides a global basis.brief summary of certain key events during the first quarter of 2015.

In October 2014,Opdivo was approved by the Company announced that it will not pursue U.S. Food and Drug Administration (FDA) approval of the dual regimen of daclatasvir and asunaprevir for the treatment of hepatitis C virus (HCV) genotype 1b patients in the U.S. and has withdrawn its New Drug Application (NDA) for asunaprevir.

In September 2014, the Company announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for Opdivo (nivolumab) inpreviously-treated advanced squamous cell non-small cell lung cancer –(NSCLC). The Company entered into several business development transactions to advance our research and development (R&D) portfolio, including the acquisition of Flexus Biosciences, Inc. (Flexus). See "Business Development" below for further discussions.

Our revenues increased by 6% in the first completed regulatory submission forquarter of 2015 as a PD-1 immune checkpoint inhibitor in this tumor type. In addition, we announced multiple regulatory milestones forresult of higher key product sales including Eliquis (apixaban)and Yervoy (ipilimumab), and the launches of the Hepatitis C Franchise and Opdivo (nivolumab) in the U.S. and European Union (EU). In the U.S., the FDA has accepted for priority review the Biologics License Application (BLA) for previously treated advanced melanoma and the Prescription Drug User Fee Act (PDUFA) goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy Designation for this indication. In the EU, the EMA validated for review the MAA for Opdivo in advanced melanoma. The application has also been granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP).

During the third quarter of 2014,2014. The sales growth for these and other key products more than offset unfavorable impacts resulting from changes in foreign currency rates, the Companyexpiration of certain licensing rights and Pfizer announced that the FDAcompetitive pressures resulting from exclusivity losses and European Commission (EC) approved Eliquis (apixaban)other factors for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and in the U.S., the FDA also approved Eliquis for the reduction Baraclude (entecavir), Sustiva (efavirenz)and Reyataz (atazanavir sulfate)in the risk of recurrent DVT and PE following initial therapy.certain markets.

In August 2014, the Company announced that the EC approved Daklinza (daclatasvir) for useThe increase in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic HCV infection. Daklinza GAAP earnings per share (EPS) from $0.56 to $0.71 was launched in Germany in August 2014 and certain other EU countries in September 2014.

In July 2014, the Company announced that the Japanese Ministry of Health, Labor and Welfare approved Daklinza and Sunvepra (asunaprevir) for Japan’s first all-oral, interferon- and ribavirin-free treatment regimen for patients with genotype 1 chronic HCV infection, particularly those with compensated cirrhosis. Daklinza and Sunvepra dual regimen was launched in Japan in September 2014.

In July 2014, the Company and Ono Pharmaceutical Co., Ltd (Ono), signed a collaboration agreementdue to jointly develop and commercialize Opdivo, Yervoy (ipilimumab) and three immunotherapy agents in early clinical developmenthigher revenues as single agents and combination regimens in Japan, South Korea and Taiwan. Also in July 2014, Ono announced that Opdivo received manufacturing and marketing approval in Japan for the treatment of unresectable melanoma. Opdivo was launched in Japan in September 2014. Opdivo is the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world.

In February 2014, the Company sold to AstraZeneca substantially all ofwell as lower expenses resulting from the diabetes business comprising our alliance with them. Revenuesdivestiture and changes in foreign currency rates. The tax impact of specified items contributed to the change in the U.S.effective tax rate. After adjusting for specified items, Non-GAAP EPS increased from $0.46 to $0.71. Our revenues and expenses (excluding research and development expenses) decreased as a result of the divestiture and a $539 million gain on the sale of the business was recognizedearnings are expected to decline in the nine months ended September 30, 2014. See "Item 1. Financial Statements—Note 3. Alliances" for further information.

Inremaining quarters of 2015 compared to the thirdfirst quarter of 2014,2015 and the Company entered into several collaboration agreementsprior year due to research and developthe expiration of our U.S. rights to OpdivoAbilify* and other approved or investigational oncology agents in combination regiments, including with Novartis, Celgene Corporation, Cytomx Therapeutics, Inc, Incyte Corporation, The University of Texas MD Cancer Center, Celldex Therapeutics, Inc., Pharmacyclics, Inc., and Janssen Research & Development, LLC, among others.(aripiprazole) on April 20, 2015.



26



Highlights
The following table summarizes our financial information:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions, except per share data2014 2013 2014 20132015 2014
Total Revenues$3,921
 $4,065
 $11,621
 $11,944
$4,041
 $3,811
Total Expenses2,913
 3,247
 9,180
 9,922
2,593
 2,826
Earnings Before Income Taxes1,008
 818
 2,441
 2,022
1,448
 985
Provision for Income Taxes276
 126
 439
 177
249
 49
Effective tax rate27.4% 15.4% 18.0% 8.8%17.2% 5.0%
          
Net Earnings Attributable to BMS          
GAAP721
 692
 1,991
 1,837
1,186
 937
Non-GAAP750
 768
 2,314
 2,177
1,193
 766
          
Diluted Earnings Per Share          
GAAP0.43
 0.42
 1.19
 1.11
0.71
 0.56
Non-GAAP0.45
 0.46
 1.39
 1.31
0.71
 0.46
          
Cash, Cash Equivalents and Marketable Securities    11,549
 6,345
11,886
 10,617

Our non-GAAP financial measures, including non-GAAP earnings and related earnings per share (EPS)EPS information, are adjusted to exclude specified items which represent certain costs, expenses, gains and losses and other items impacting the comparability of financial results. For a detailed listing of all specified items and further information and reconciliations of non-GAAP financial measures see “—Non-GAAP Financial Measures” below.Measures.”


21



Product and Pipeline Developments
We manage our research and developmentR&D programs on a portfolio basis, investing resources in each stage from early discovery through late-stage development. We continually evaluate our portfolio of research and developmentR&D assets to ensure that there is an appropriate balance of early-stageearly- and late-stage programs to support future growth. We consider our research and developmentR&D programs that have entered into Phase III development to be significant, as these programs constitute our late-stage development pipeline. These programs include both investigational compounds in Phase III development for initial indications and marketed products in Phase III development for additional indications or formulations. The following are the recent significant developments in our marketed products and our late-stage pipeline:

Opdivo - a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells that is being investigated as an anti-cancer treatment. Opdivo is part of our alliance with Ono.
In September 2014,April 2015, the Company announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion recommending that Opdivo be granted approval for use in patients with advanced (unresectable or metastatic) melanoma. The opinion will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
In April 2015, the Company announced positive results from CheckMate-037, a Phase 3 randomized, controlled open-label study ofII trial (CheckMate-069), evaluating the Opdivo+Yervoy regimen versus investigator’s choice chemotherapy (ICC)Yervoy alone in patients with previously untreated advanced melanoma who were previouslymelanoma. Patients with BRAF wild-type mutation status treated with the Opdivo+Yervoy. Based on regimen experienced a planned interim analysis of the co-primary endpoint, thehigher objective response rate was 32% (95% CI = 24, 41)(ORR) of 61% (n=44/72) – the primary study endpoint – compared to 11% (n=4/37) for patients administered Yervoy monotherapy (P<0.001). Complete responses were also reported in 22% (n=16) of patients with BRAF wild-type mutation status administered the OpdivoOpdivo+Yervoy arm (n="120")regimen and 11% (95% CI = 4, 23) in the ICC reference arm (n="47")no patients who received Yervoy monotherapy. Similar results were also observed in patients with at least six months of follow up.BRAF mutation-positive patients.
In September 2014,April 2015, the Company announced multiple regulatory milestonesan open-label, randomized Phase III study evaluating Opdivo versus docetaxel in previously treated patients with advanced non-squamous NSCLC was stopped early because an assessment conducted by the independent Data Monitoring Committee concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm.
In March 2015, the Company announced the FDA approved Opdivo for the treatment of patients with advanced squamous cell NSCLC with progression on or after platinum-based chemotherapy. Opdivo is the first and only PD-1 therapy to demonstrate overall survival (OS) in previously treated advanced squamous cell NSCLC. Opdivo demonstrated significantly superior OS vs. docetaxel, with a 41% reduction in the U.S.risk of death (hazard ratio: 0.59 [95% CI: 0.44, 0.79; p=0.00025]), in a prespecified interim analysis of a Phase III clinical trial. The median OS was 9.2 months in the Opdivo arm (95% CI: 7.3, 13.3) and 6 months in the EU.docetaxel arm (95% CI: 5.1, 7.3).
◦
In the EU, the EMA validated for review the MAA for Opdivo in non-small cell lung cancer - the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type.
◦
In the U.S., the FDA has accepted for priority review the BLA for previously treated advanced melanoma. The PDUFA goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy Designation for this indication.
◦
In the EU, the EMA validated for review the MAA for Opdivo in advanced melanoma. The application has also been granted accelerated assessment by the EMA’s CHMP.


27

Yervoy - a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma
In March 2015, the Company announced the FDA has accepted for filing and review the sBLA for Yervoy for the adjuvant treatment of patients with stage 3 melanoma who are at high risk of recurrence following complete surgical resection. The projected FDA action date is October 28, 2015.


Hepatitis C Portfolio - Daklinza (Daclatasvir(daclatasvir (DCV)) - an NS5A replication complex inhibitor; Sunvepra (Asunaprevir(asunaprevir (ASV)) - an NS3 protease inhibitor; BMS-791325and Beclabuvir (BCV) - an NS5B non-nucleoside polymerase inhibitor in development
In October 2014,April 2015, the Company announced that it will not pursue the FDA approvalprimary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week, combination of the dual regimen of DCVdaclatasvir and ASVsofosbuvir once-daily with ribavirin for the treatment of HCV genotype 1b patients in the U.S. and has therefore withdrawn its NDA for asunaprevir. The Company will continue to pursue the FDA approval of DCV, which is currently being investigated globally in multiple treatment regimens for HCV patients with high unmet needs.
In August 2014, the Company announced that the EC has approved Daklinza for use in combinationchronic hepatitis C virus (HCV) with other medicinal products across genotypes 1, 2, 3 and 4 for the treatmenteither advanced cirrhosis or post-liver transplant recurrence of chronic HCV infection in adults. Daklinza, when used in combination with sofosbuvir, is an all-oral, interferon-free regimen that provided cure rates of up to 100% in clinical trials, including patients with advanced liver disease, genotype 3 and those who have previously failed treatment with protease inhibitors. Daklinza is the first NS5A complex inhibitor approved in the EU and is available for use in combination with other medicinal products, providing a shorter treatment duration (12 or 24 weeks) compared to 48 weeks of treatment with interferon- and ribavirin-based regimens.HCV. Sofosbuvir is a product of Gilead Sciences, Inc.
(Gilead).
In July 2014,March 2015, the Company announced that the Japanese Ministryresubmitted new drug application (NDA) for daclatasvir has been accepted for review by the FDA for use in combination with sofosbuvir for the treatment of Health, Laborchronic HCV genotype 3. The FDA will review the submission within a six-month timeframe.
In February 2015, the Company announced results from ALLY-2, a Phase III clinical trial evaluating the investigational once-daily combination of daclatasvir and Welfare approved Daklinza and Sunvepra as a new HCVsofosbuvir for the treatment that can lead to a cure for many patients in Japan who currently have no treatment options. The Daklinza + Sunvepra dual regimen is Japan’s first all-oral, interferon- and ribavirin-free treatment regimen forof patients with chronic HCV coinfected with the human immunodeficiency virus (HIV) – a patient population that historically has been challenging to treat in large part due to potential drug-drug interactions between the therapy regimens used to treat each infection. Among ALLY-2 patients treated for 12 weeks (treatment-naïve and -experienced), 97% (n=149/153) achieved cure (sustained virologic response 12 weeks after treatment; SVR12). The study met the primary endpoint, with 96% (n=80/83) of treatment-naïve genotype 1 chronicpatients achieving SVR12. Treatment with daclatasvir in combination with sofosbuvir in this study showed high SVR rates, with no discontinuations due to adverse events, and no serious adverse events related to study medications throughout the treatment phase.
In February 2015, the FDA notified the Company of its intention to rescind the Breakthrough Therapy Designation for certain genotype 1 HCV infection, including thoseregimens related to daclatasvir and other investigational BMS therapies. This will not impact our current submission/resubmission timetable of the NDA for daclatasvir in combination with compensated cirrhosis. The indicationsother antiviral agents for Daklinza and Sunvepra in Japan are for: (1) patients who are ineligible or intolerant to interferon-based therapy, and (2) patients who have failed to respond to interferon-based therapy.the treatment of HCV.

22




SustivaReyataz (efavirenz)Franchise —- a non-nucleoside reverse transcriptaseprotease inhibitor for the treatment of the HIV, which includes SustivaReyataz , an antiretroviral drug, and bulk efavirenz, which is also included in the combination therapy, Atripla* Evotaz(efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate (atazanavir 300 mg and cobicistat 150 mg), a product sold through our joint venture with Gilead.
In October 2014,January 2015, the Company announced it has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in Sustiva and Atripla*, and that loss of exclusivity in the U.S. for efavirenz is not expected to occur until December 2017.

Eliquis - an oral Factor Xa inhibitor, targeted at stroke prevention in nonvalvular atrial fibrillation (NVAF) and the prevention and treatment of venous thromboembolic (VTE) disorders. Eliquis is part of our alliance with Pfizer.
In August 2014, the Company and Pfizer announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (Apixaban after the initial Management of PuLmonary embolIsm and deep vein thrombosis with First-line therapY-EXTended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes DVT and PE. Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.
In August 2014, the Company and Pfizer announced that the FDA approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy.
In July 2014, the Company and Pfizer announced that the EC approved EliquisEvotaz for the treatment of DVTthe HIV-1 infection in adults, a once-daily single tablet two drug regimen combining Reyataz and PETybost*. Tybost* is a product of Gilead.

BMS-663068 - an investigational compound which has shown antiviral activity in adults.
HIV-1 infected individuals.
In July 2014,February 2015, the Company and Pfizer announced that the first patient has been enrolled intodata from a Phase IV clinicalIIb trial called EMANATE assessingof BMS-663068, which is designed as an HIV-1 attachment inhibitor. In the effectiveness study, which compared BMS-663068 to a pharmacoenhanced protease inhibitor (Reyataz and safetyritonavir), virologic response rates (HIV-1 RNA <50 c/mL) and immunologic reconstitution were similar across the BMS-663068 and Reyataz/ritonavir arms of the trial through 48 weeks. Specifically, 61-82% of BMS-663068 patients had HIV-1 RNA levels <50 c/mL, compared to 71% of EliquisReyataz in/ritonavir patients at week 48 (mITT FDA snapshot analysis). HIV-1 RNA levels <50 c/mL typically indicate virus replication is undetectable. The Company also initiated the Phase III studies of BMS-663068.

Orencia (abatacept) - a fusion protein indicated for adult patients with NVAF undergoing cardioversion.moderate to severe active rheumatoid arthritis (RA) and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
In April, the CHMP adopted a positive opinion approving the ClickJect Pre-Filled Pen, a new autoinjector delivery device for Orencia for use in adult patients in the E.U. who have moderate to severe active rheumatoid arthritis in combination with methotrexate after inadequate disease-modifying anti-rheumatic drug response.

Business Development
Business development transactions allow us to focus our resources behind our growth opportunities that drive the greatest long-term value. From a disease standpoint, we are focused on the following core therapeutic areas: oncology, virology, immunology, specialty cardiovascular disease, fibrosis and genetically defined diseases. Recent business development transactions are summarized below:

Flexus
In April, BMS acquired all of the outstanding shares of Flexus, a privately held biotechnology company focused on discovering and developing novel anti-cancer therapeutics. The acquisition provides BMS with full rights to F001287, a preclinical small molecule IDO1-inhibitor targeted immunotherapy with potential to be used in combination with BMS's immuno-oncology portfolio. In addition, the transaction included Flexus' IDO/TDO discovery program which includes its IDO-selective, IDO/TDO dual and TDO-selective compounds.

uniQure Biopharma N.V. (uniQure)
In April, the Company announced an agreement with uniQure that provides BMS with exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases. The collaboration includes uniQure’s proprietary gene therapy program for congestive heart failure that is intended to restore the heart’s ability to synthesize S100A1, a calcium sensor and master regulator of heart function, and thereby improve clinical outcomes for patients with reduced ejection fraction. The agreement also includes the potential for target-exclusive collaboration in other disease areas. In total, the companies may collaborate on 10 targets, including S100A1. BMS will be solely responsible for global commercialization of all products from the collaboration. The Company also announced it was making an initial equity investment in uniQure’s affiliate, uniQure, for a number of shares that will equal 4.9% of the total number of shares of uniQure outstanding following such issuance, at a purchase price of $33.84 per share, or at least $32 million in total. The Company will acquire an additional 5.0% ownership before December 31, 2015, at a 10% premium, and will be granted two warrants to acquire up to an additional 10% equity interest, at a premium, based on additional targets being introduced into the collaboration. uniQure and Bristol-Myers Squibb anticipate the collaboration agreement to be effective during the second quarter of 2015. The effectiveness of the collaboration agreement is subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act. The initial issuance by uniQure of equity to the Company is also anticipated to close in the second quarter of 2015 and is subject to the approval by the shareholders of uniQure.

Novo Nordisk A/S (Novo Nordisk)
In March, the Company acquired an exclusive global license from Novo Nordisk to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases.


2823



Bavarian Nordic A/S (Bavarian Nordic)
In March, the Company acquired an exclusive option to globally license and commercialize Prostvac*, Bavarian Nordic’s investigational Phase III prostate-specific antigen-targeting cancer immunotherapy in development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

Rigel Pharmaceuticals, Inc. (Rigel)
In February, the Company announced an agreement with Rigel for the discovery, development and global commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system’s activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Opdivo and Yervoy.

California Institute for Biomedical Research (Calibr)
In January, the Company announced a worldwide research collaboration with Calibr to develop novel small molecule anti-fibrotic therapies, and an exclusive global license agreement that allows the Company to develop, manufacture and commercialize Calibr's preclinical compounds resulting from the collaboration.

RESULTS OF OPERATIONS

Total Revenues
Three Months Ended September 30, Nine Months Ended September 30,
  2014 vs. 2013   2014 vs. 2013Three Months Ended March 31,
Total Revenues Analysis of % Change Total Revenues Analysis of % ChangeTotal Revenues 2015 vs. 2014
Dollars in Millions2014 2013 Total Change Volume Price Foreign Exchange 2014 2013 Total Change Volume Price Foreign Exchange2015 2014 Total Change Foreign Exchange
United States$1,968
 $2,037
 (3)% (8)% 5 % —
 $5,634
 $6,053
 (7)% (11)% 4 % —
$2,044
 $1,765
 16 % —
Europe814
 985
 (17)% (12)% (6)% 1 % 2,670
 2,881
 (7)% (4)% (5)% 2 %782
 948
 (18)% (16)%
Rest of the World838
 805
 4 % 8 % (1)% (3)% 2,479
 2,405
 3 % 9 % (2)% (4)%1,019
 830
 23 % (13)%
Other(a)
301
 238
 26 % N/A
 N/A
 —
 838
 605
 39 % N/A
 N/A
 —
196
 268
 (27)% N/A
Total$3,921
 $4,065
 (4)% (4)% —
 —
 $11,621
 $11,944
 (3)% (3)% —
 —
$4,041
 $3,811
 6 % (7)%

(a)Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
No single country outside the U.S. contributed more than 10% of total revenues during the ninethree months ended September 30, 2014March 31, 2015 and 20132014. Our business is typically not seasonal.
The change in U.S. revenues attributed to volume for both periods resulted from the diabetes business divestitureincrease in February 2014 partially offset byour share of Abilify* revenues (10%) and higher average net selling prices for key products (5%).The remaining change resulted from increased demand for Eliquis, Sprycel (dasatinib)and Yervoy. The change and the launch of Opdivo in U.S. revenues attributed to price for both periods was due to higher average net selling prices for Abilify*(aripiprazole) and other key products.December 2014 offset by the diabetes business divestiture. See “—Revenues of Products”Product Revenues” for further discussions.discussion.
The change in Europe revenues in both periods resulted from the expiration of commercialization rights to Abilify* in the EU in June 2014 the diabetes business divestiture in February 2014 and loss of exclusivity of Sustiva in 2013,unfavorable foreign exchange, partially offset by higher demand for most other key products, particularly YervoyEliquis , andEliquis,Orencia Yervoy, and the launch of Daklinza in Germany and certain other EU countries.countries in the third quarter of 2014. In addition, the change in revenues in both periods waswere negatively impacted by fiscal challenges in many European countries as healthcare payers, including government agencies have reduced and are expected to continuecontinued to reduce healthcare costs through actions that directly or indirectly impose additional price reductions. These measures include mandatory discounts, rebates, and other restrictive measures. Both periods were impacted by favorable foreign exchange.
The change in revenues attributed to volume in Rest of the World revenues resulted from higher demand for key products, particularly Eliquis, Yervoy,Sprycel and the launch of Daklinza and Sunvepra dual regimen in Japan which wasin the third quarter of 2014 and increased demand for key products, particularly Eliquis, partially offset by the diabetes business divestiture. Both periods were impacted by unfavorable foreign exchange (primarily in Japan).
Other revenues increased in both periodsdecreased due to higher royaltiesthe expiration of certain royalty and revenues from alliances including mature brands and over-the-counter products.alliance agreements in 2014. Certain alliance and other revenues are expected to decline by approximately $400 million in 2015 and continue to decline in 2016 upon the expiration of the related royalty and alliance agreements.


2924



We recognize revenue net of gross-to-net adjustments that are further described in “—Critical Accounting Policies” in the Company’s 20132014 Form 10-K. Our share of Abilify* and Atripla* is reflected net of all gross-to-net adjustments in alliance and other revenues. Although not presented as a gross-to-net adjustment in the below tables, our share of Abilify* and Atripla* gross-to-net adjustments were $410$567 million and $323$359 million for the three months ended September 30, 2014March 31, 2015 and 2013, respectively, and $1,174 million and $957 million for the nine months ended September 30, 2014 and 2013, respectively. The activities and ending reserve balancesThese adjustments increased because of our increase in revenue sharing for each significant category of gross-to-net adjustments were as follows:Abilify* in the U.S.
Dollars in MillionsCharge-Backs Related to Government Programs Cash Discounts Managed Healthcare Rebates and Other Contract Discounts Medicaid Rebates Sales Returns Other Adjustments TotalCharge-Backs and Cash Discounts Medicaid and Medicare Rebates Sales Returns Other Rebates, Discounts and Adjustments Total
Balance at January 1, 2014$37
 $12
 $147
 $227
 $279
 $236
 $938
Balance at January 1, 2015$56
 $268
 $232
 $351
 $907
Provision related to sales made in:                      
Current period454
 104
 266
 299
 68
 412
 1,603
200
 154
 17
 210
 581
Prior periods—
 —
 1
 (23) 3
 (10) (29)—
 (8) 1
 2
 (5)
Returns and payments(454) (103) (287) (255) (77) (373) (1,549)(202) (97) (24) (171) (494)
Balance at September 30, 2014$37
 $13
 $127
 $248
 $273
 $265
 $963
Impact of foreign currency translation—
 —
 (1) (24) (25)
Balance at March 31, 2015$54
 $317
 $225
 $368
 $964

The reconciliation of gross product sales to net product sales by each significant category of gross-to-net adjustments was as follows:

Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Gross product sales$3,400
 $3,570
 $9,994
 $10,543
$3,635
 $3,311
Gross-to-Net Adjustments          
Charge-backs related to government programs(165) (143) (454) (409)
Cash discounts(37) (39) (104) (113)
Managed healthcare rebates and other contract discounts(94) (126) (267) (351)
Medicaid rebates(93) (78) (276) (215)
Charge-backs and cash discounts(200) (172)
Medicaid and Medicare rebates(146) (126)
Sales returns(38) (16) (71) (53)(18) (13)
Other adjustments(130) (143) (402) (396)
Other rebates, discounts and adjustments(212) (193)
Total Gross-to-Net Adjustments(557) (545) (1,574) (1,537)(576) (504)
Net product sales$2,843
 $3,025
 $8,420
 $9,006
$3,059
 $2,807

Changes in the gross-to-net adjustments are primarily a function of changes in sales mix and contractual and legislative discounts and rebates.
Managed healthcare rebates
Charge-backs and other contractcash discounts decreasedincreased primarily due to the divestiture ofhigher Eliquis sales in 2015.
Medicaid and Medicare rebates increased primarily due to higher Eliquis sales in 2015 partially offset by the diabetes business divestiture in February 2014.
Medicaid rebates increased due to incremental discounts from price increases taken in excess of inflation; higher program participation rates and higher provision reversals related to sales made in prior periods in 2013.
The U.S. sales return reservesreserve for Plavix* and Avapro*/Avalide*at September 30, 2014 were $133March 31, 2015 was $75 million and werewas determined after considering several factors including estimated inventory levels in the distribution channels. In accordance with Company policy, these products arethis product is eligible to be returned between six months prior to and twelve months after product expiration. Adjustments to these reservesthis reserve might be required in the future for revised estimates to various assumptions including actual returns.
Other rebates, discounts and adjustments increased primarily due to higher government rebates in non-U.S. markets.

3025



Product Revenues

Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 % Change % Change Attributable to Foreign Exchange 2014 2013 % Change % Change Attributable to Foreign Exchange2015 2014 % Change % Change Attributable to Foreign Exchange
Virology                      
Baraclude (entecavir)$325
 $378
 (14)% —
 $1,100
 $1,115
 (1)% —
$340
 $406
 (16)% (6)%
U.S.40
 67
 (40)% —
 194
 208
 (7)% —
46
 70
 (34)% —
Non-U.S.285
 311
 (8)% —
 906
 907
 —
 —
294
 336
 (13)% (8)%
                      
Hepatitis C Franchise (daclatasvir and asunaprevir)
49
 —
 N/A
 N/A
 49
 —
 N/A
 N/A
264
 —
 N/A
 N/A
Non-U.S.49
 —
 N/A
 N/A
 49
 —
 N/A
 N/A
264
 —
 N/A
 N/A
                      
Reyataz (atazanavir sulfate)338
 375
 (10)% (1)% 1,044
 1,167
 (11)% (1)%
Reyataz (atazanavir sulfate) Franchise294
 344
 (15)% (6)%
U.S.169
 189
 (11)% —
 513
 582
 (12)% —
143
 176
 (19)% —
Non-U.S.169
 186
 (9)% (2)% 531
 585
 (9)% (2)%151
 168
 (10)% (12)%
                      
Sustiva (efavirenz) Franchise357
 389
 (8)% —
 1,037
 1,187
 (13)% 1 %290
 319
 (9)% —
U.S.284
 259
 10 % —
 778
 785
 (1)% —
234
 228
 3 % —
Non-U.S.73
 130
 (44)% —
 259
 402
 (36)% 2 %56
 91
 (38)% (2)%
                      
Oncology                      
Erbitux* (cetuximab)187
 183
 2 % N/A
 542
 516
 5 % N/A
165
 169
 (2)% —
U.S.175
 180
 (3)% —
 511
 506
 1 % —
157
 158
 (1)% —
Non-U.S.12
 3
 **
 N/A
 31
 10
 **
 N/A
8
 11
 (27)% —
                      
Opdivo (nivolumab)1
 —
 N/A
 N/A
 1
 —
 N/A
 N/A
40
 —
 N/A
 N/A
U.S.38
 —
 N/A
 —
Non-U.S.1
 —
 N/A
 N/A
 1
 —
 N/A
 N/A
2
 —
 N/A
 N/A
                      
Sprycel (dasatinib)385
 316
 22 % (1)% 1,095
 915
 20 % (1)%375
 342
 10 % (9)%
U.S.179
 134
 34 % —
 487
 384
 27 % —
181
 145
 25 % —
Non-U.S.206
 182
 13 % (2)% 608
 531
 15 % (2)%194
 197
 (2)% (17)%
                      
Yervoy (ipilimumab)350
 238
 47 % —
 942
 700
 35 % 1 %325
 271
 20 % (9)%
U.S.191
 130
 47 % —
 510
 429
 19 % —
181
 146
 24 % —
Non-U.S.159
 108
 47 % 1 % 432
 271
 59 % 1 %144
 125
 15 % (21)%
                      
Neuroscience                      
Abilify* (aripiprazole)449
 569
 (21)% —
 1,544
 1,654
 (7)% —
554
 540
 3 % —
U.S.407
 378
 8 % —
 1,149
 1,084
 6 % —
508
 325
 56 % —
Non-U.S.42
 191
 (78)% (1)% 395
 570
 (31)% 1 %46
 215
 (79)% (2)%
                      
Immunoscience                      
Orencia (abatacept)444
 375
 18 % (1)% 1,209
 1,047
 15 % (1)%400
 363
 10 % (7)%
U.S.292
 246
 19 % —
 775
 698
 11 % —
259
 229
 13 % —
Non-U.S.152
 129
 18 % (2)% 434
 349
 24 % (4)%141
 134
 5 % (19)%
                      
Cardiovascular                      
Eliquis (apixaban)216
 41
 **
 N/A
 493
 75
 **
 N/A
355
 106
 **
 N/A
U.S.113
 27
 **
 —
 268
 49
 **
 —
200
 61
 **
 —
Non-U.S.103
 14
 **
 N/A
 225
 26
 **
 N/A
155
 45
 **
 N/A
                      
Diabetes Alliance42
 432
 (90)% —
 248
 1,228
 (80)% —
U.S.—
 308
 (100)% —
 114
 920
 (88)% —
Non-U.S.42
 124
 (66)% —
 134
 308
 (56)% —
               
Mature Products and All Other778
 769
 1 % (1)% 2,317
 2,340
 (1)% —
639
 951
 (33)% (6)%
U.S.118
 119
 (1)% —
 335
 408
 (18)% —
97
 227
 (57)% —
Non-U.S.660
 650
 2 % (1)% 1,982
 1,932
 3 % —
542
 724
 (25)% (7)%
****    Change in excess of 100%.


3126


Baraclude — an oral antiviral agent for the treatment of chronic hepatitis BB.
U.S. revenues decreased in both periods due tofollowing the launch of generic entecavir by Teva Pharmaceutical Industries Ltd. in September 2014, partially offset by higher average net selling prices. We expecta continued rapid decline in Baraclude sales in the U.S in the next quarter.
2014.
International revenues decreased in both periods primarily due to unfavorable foreign exchange and lower demand in China.demand.
Hepatitis C Franchise — Daklinza - an NS5A replication complex inhibitor; Sunvepra - an NS3 protease inhibitorinhibitor.
Daklinza was launched in Germany in August 2014 and certain other EU countries in September 2014 following its August 2014 approval.the third quarter of 2014. Daklinza and Sunvepra dual regimen was launched in Japan in September 2014 following its July 2014 approval.the third quarter of 2014.
Reyataz Franchise — a protease inhibitor for the treatment of HIV, which includes Reyataz and is also included in the combination therapy, Evotaz (atazanavir 300 mg and cobicistat 150 mg).
U.S. revenues decreased in both periods due to lower demand resulting from competitors' products.increased competition.
International revenues decreased in both periods due to lower demand resulting from increased competition and unfavorable foreign exchange partially offset by the timing of government purchases in certain countries.
Sustiva Franchise — a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, which includes Sustiva, an antiretroviral drug, and bulk efavirenz, which is also included in the combination therapy, Atripla*, a product sold through our joint venture with Gilead.
U.S. revenues increased in the three months ended September 30, 2014 due to higher average net selling prices. U.S. revenues decreased in the nine months ended September 30, 2014 as lower demand wasprices partially offset by higher average net selling prices.lower demand.
International revenues decreased in both periods due tofollowing Sustiva'sloss of exclusivity in Europe in November 2013, which continues to negatively impactedimpact demand, average net selling prices and AtriplaAtripla** revenue sharing.
Erbitux* — a monoclonal antibody designed to exclusively target and block the Epidermal Growth Factor Receptor, which is expressed on the surface of certain cancer cells in multiple tumor types as well as normal cells and is currently indicated for use in the treatment of patients with certain types of metastatic colorectal cancer and squamous cell carcinoma of the head and neck.Erbitux* is part of our alliance with Eli Lilly and Company.
U.S. revenues decreased in the three months ended September 30, 2014 due to lower average net selling prices. U.S. revenues in the nine months ended September 30, 2014 remained relatively flat.
Opdivo — a fully human monoclonal antibody that binds to the programmed death receptor-1 (PD-1) on T and NKT cells that is being investigated as an anti-cancer treatment.Opdivo is part of our alliance with Ono.
Opdivo was launched in the U.S. in December 2014 and Japan in September 2014 in Japan following its July 2014 approval for the treatment of unresectable melanoma.Opdivo was approved in the U.S. in March 2015 for the treatment of advanced squamous cell NSCLC.
Sprycel — an oral inhibitor of multiple tyrosine kinases indicated for the first-line treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase and the treatment of adults with chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy, including Gleevec* (imatinib meslylate).Sprycel is part of our alliance with Otsuka Pharmaceutical Co., Ltd (Otsuka).
U.S. revenues increased in both periods due to higher demand.
International revenues increased in both periodsdecreased due to unfavorable foreign exchange partially offset by higher demand.
Yervoy — a monoclonal antibody for the treatment of patients with unresectable (inoperable) or metastatic melanomamelanoma.
U.S. revenues increased in both periods due to higher demand. The first quarter of 2013 included $27 million of revenues that were previously deferred.
International revenues increased in both periods due to higher demand.demand partially offset by unfavorable foreign exchange.
Abilify* — an antipsychotic agent for the treatment of schizophrenia, bipolar mania disorder and major depressive disorder and is part of our alliance with Otsukadisorder.
U.S. revenues increased in both periods primarily due to higher average net selling prices partially offset by the reductionan increase in our contractual share of Abilify* revenues from 34%33% in 20132014 to 33%.50% in 2015. Our commercialization rights to Abilify* expired in the U.S. on April 20, 2015. As a result, we will no longer record Abilify* revenues. Sales return reserve requirements will likely increase in the second quarter as a result of the expected loss of exclusivity for Abilify* in the U.S. expire in April 2015 upon the expected loss of product exclusivity which will result in a significant decline in Abilify* revenues.
International revenues decreased in both periods primarily due tofollowing the expiration of our commercialization rights in June 2014 in the EU and Otsuka becoming the principal for the end customer sales in certainmost markets. As a result, these revenues are expected to continue to decline for the remainder of 2014.

32


Orencia — a fusion protein indicated for adult patients with moderate to severe active RA and is also indicated for reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
U.S. revenues increased in both periods primarily due to higher average net selling prices and higher demand for the subcutaneous formulation.prices.
International revenues increased in both periods primarily due to higher demand for the subcutaneous formulation.formulation partially offset by unfavorable foreign exchange.

27


Eliquis — an oral Factor Xa inhibitor, targeted at stroke prevention in adult patients with NVAFnon-valvular atrial fibrillation and the prevention and treatment of VTEvenous thromboembolic disorders.Eliquis is part of our alliance with Pfizer.
U.S. and international revenues continuedincreased due to increase in both periods following the 2013 launches in most major markets for the reduction of the risk of stroke and systemic embolism for patients with NVAF.higher demand.
Diabetes Alliance — includes Bydureon*, Byetta*, Farxiga*, Onglyza*/Kombiglyze*, Myalept*, and Symlin*, whichwere part of our alliance with AstraZeneca.
BMS sold its diabetes businessInternational revenues increased due to AstraZeneca on February 1, 2014. See "Item 1. Financial Statements— Note 3. Alliances" for further information.higher demand.
Mature Products and All Other — includes all other products, including those which have lost exclusivity in major markets, the Diabetes Alliance products, over-the-counter brands and royalty revenue.
U.S. revenues decreased in both periods due to lower demandthe diabetes business divestiture in February 2014 and the continued generic erosion of othercertain products.
International revenues increased in both periodsdecreased primarily due to revenues attributed tothe expiration of certain alliances, which were partially offset by theroyalty and alliance agreements as well as continued generic erosion of other products.products and the diabetes business divestiture in February 2014.
Estimated End-User Demand
Pursuant to the Securities and Exchange Commission (SEC) Consent Order described in our 20132014 Annual Report on Form 10-K, we monitor the level of inventory levels on hand in the U.S. wholesaler distribution channel and outside of the U.S. in the direct customer distribution channel. We are obligated to disclose products with levels of inventory in excess of one month on hand or expected demand, subject to a de minimis exception. Estimated levels of inventory in the distribution channel in excess of one month on hand for the following products were not material to our results of operations as of the dates indicated.

ReyatazOpdivo had 1.1 months of inventory on hand internationally at June 30, 2014 compared to 1.02.0 months of inventory on hand at March 31, 2014.2015 in the U.S. to support the product launch of the additional lung indication. The level of inventory exceeds one month on hand primarily dueis expected to government purchasing patterns in Brazil.be worked down as demand increases post launch.

EfferalganDafalgan,, an analgesic product sold principally in Europe, had 1.1 months of inventory on hand at direct customers internationally at June 30,December 31, 2014 compared to 0.91.0 months of inventory on hand at March 31,September 30, 2014. The level of inventory on hand was primarily due to the ordering patterns of pharmacists in France.

Maxipime, an antibiotic product, had 1.2 months of inventory on hand internationally at June 30, 2014 compared to 0.6 months of inventory on hand at March 31, 2014. The level of inventory on hand was primarily due to lower demand in China and increased wholesaler purchases in Japan because of competitors' supply issues.

In the U.S., we generally determine our months on hand estimates using inventory levels of product on hand and the amount of out-movement provided by our three largest wholesalers and our distributors. Our three largest wholesalers account for approximately 90%95% of total gross sales of U.S. products. Factors that may influence our estimates include generic competition, wholesaler purchases in light of increases in wholesaler list prices, new product launches, new warehouse openings by wholesalers and new customer stockings by wholesalers. In addition, these estimates are calculated using third-party data, which may be impacted by their recordkeeping processes.

Our non-U.S. businesses have significantly more direct customers. Limited information on direct customer product level inventory and corresponding out-movement information and the reliability of third-party demand information, where available, varies widely. When direct customer product level inventory, ultimate patient/consumer demand or out-movement data does not exist or is otherwise not available, we have developed a variety of methodologies to estimate such data, including using historical sales made to direct customers and third-party market research data related to prescription trends and end-user demand. Accordingly, we rely on a variety of methods to estimate direct customer product level inventory and to calculate months on hand. Factors that may affect our estimates include generic competition, seasonality of products, direct customer purchases in light of price increases, new product launches, new warehouse openings by direct customers, new customer stockings by direct customers and expected direct customer purchases for governmental bidding situations. As a result, all of the information required to estimate months on hand in the direct customer distribution channel for non-U.S. businesses for the quarter ended September 30, 2014March 31, 2015 is not available prior to the filing of this quarterly report on Form 10-Q. We will disclose any product with inventory levels of inventory in excess of one month on hand or expected demand for the current quarter, subject to a de minimis exception, in the next annualquarterly report on Form 10-K.10-Q.

33




Expenses
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 % Change 2014 2013 % Change2015 2014 % Change
Cost of products sold$1,007
 $1,175
 (14)% $2,966
 $3,346
 (11)%$847
 $968
 (13)%
Marketing, selling and administrative1,029
 980
 5 % 2,937
 3,016
 (3)%894
 957
 (7)%
Advertising and product promotion171
 194
 (12)% 521
 601
 (13)%135
 163
 (17)%
Research and development983
 893
 10 % 3,345
 2,774
 21 %1,016
 946
 7 %
Other (income)/expense(277) 5
 **
 (589) 185
 **
(299) (208) 44 %
Total Expenses$2,913
 $3,247
 (10)% $9,180
 $9,922
 (7)%$2,593
 $2,826
 (8)%


**    Change is in excess of 100%
28



Cost of products sold decreased in both periods primarily due to favorable foreign exchange, the diabetes business divestiture in February 2014 ($78 million) and a reduction of previously accrued royalties ($61 million) partially offset by higher Eliquisprofit sharing royalties for other alliances and accelerated depreciation for certain manufacturing facilities.($125 million). Cost of products sold as a percentage of total revenues was 25.7%21.0% and 28.9%25.4% in the three months ended September 30,March 31, 2015 and 2014, and 2013, respectively, and 25.5% and 28.0% in the nine months ended September 30, 2014 and 2013, respectively.

Marketing, selling and administrative expenses increaseddecreased during the three months ended September 30, 2014March 31, 2015 primarily due to additional expenses related to the Branded Prescription Drug Fee in the third quarter of 2014 and decreased during the nine months ended September 30, 2014 due to lower spending throughout 2014 as a result of the diabetes business divestiture and favorable foreign exchange partially offset by additional sales-related activities supporting Eliquis, Yervoy, Opdivo and the Hepatitis C Franchise.

On July 28, 2014, the IRS issued final rules and regulations for the Branded Prescription Drug Fee, an annual non-tax-deductible fee payable to the federal government under the Affordable Care Act based on an allocation of a company’s market share for branded prescription drugs sold to certain government programs in the prior year. The final rules accelerated the expense recognition criteria for the fee obligation from the year in which the fee is paid, to the year in which the market share used to allocate the fee is determined. This change will require BMS and other industry participants to recognize an additional year of expense in 2014. As a result, an additional expense of $112 million was recognized during the three and nine months ended September 30, 2014, including $96 million in marketing, selling and administrative expenses and $16 million in other expense. The final rules and regulations will not change the amount or timing of annual fees to be paid.

Advertising and product promotion expenses decreased in both periods followingduring the three months ended March 31, 2015 primarily due to the diabetes business divestiture.divestiture and favorable foreign exchange.

Research and development expenses increased due to $343upfront payments of $160 million IPRD impairment charges, a $148 million charge for the acquisition of iPieriannew alliance and licensing agreements in the first halfthree months ended March 31, 2015 partially offset by favorable foreign exchange. The prior period included $33 million of 2014,in process research and upfront and contingent milestone payments of $80 million in 2014 (including $65 million in the third quarter of 2014). See "Item 1. Financial Statements— Note 4. Acquisitions and Note 14. Other Intangible Assets"development impairment charges. Refer to "Business Development" for further information.

Intangible assets are tested for impairment whenever current facts or circumstances warrant a review, although IPRD is required to be tested annually. Intangible assets are highly vulnerable to impairment charges, particularly newly acquired assets for recently launched products or IPRD. These assets are initially measured at fair value and therefore a reduction in expectations used indiscussion on the valuations could potentially lead to an impairment.  Some of the more common potential risks leading to impairment include competition, earlier than expected loss of exclusivity, pricing pressures, adverse regulatory changes or clinical trial results, higher development or other operating costs, inability to achieve expected sales levels or synergies, changes in tax laws or other macro-economic changes. We operate in a very dynamic market and regulatory environment in which events can occur causing our expectations to change quickly and thus leading to potential impairment charges.new arrangements.

Other (income)/expense includes:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Interest expense$50
 $46
 $150
 $146
$51
 $54
Investment income(20) (23) (71) (76)(30) (23)
Provision for restructuring35
 6
 72
 212
12
 21
Litigation charges/(recoveries)10
 17
 19
 (5)
Litigation charges12
 29
Equity in net income of affiliates(12) (42) (81) (128)(26) (36)
Out-licensed intangible asset impairment18
 —
 18
 —
13
 —
Gain on sale of product lines, businesses and assets(315) —
 (567) (1)(154) (259)
Other alliance and licensing income(102) (31) (354) (120)(161) (108)
Pension curtailments, settlements and special termination benefits28
 37
 137
 138
27
 64
Other31
 (5) 88
 19
(43) 50
Other (income)/expense$(277) $5
 $(589) $185
$(299) $(208)

Provision for restructuring was primarily attributable to employee termination benefits including costs for specialty care transformation initiatives in 2014 and sales force reductions in 2013 following the restructuring of the Sanofi and Otsuka agreements. See "Item 1. Financial Statements—Note 7. Restructuring" for further details including expected future costs.
Equity in net income of affiliates includes a $16 million impact of the additional Branded Prescription Drug Fee in the third quarter of 2014.
Gain on sale of product lines, businesses and assets resulted primarily from the sale of certain mature and other over-the-counter products in 2015 and the diabetes business divestiture, including the transfer of the China business in the third quarter of 2014. See "Item 1. Financial Statements—Note 3. Alliances" for further details.
Other allianceAlliance and licensing income increased primarily dueincludes royalties, amortization of deferred income attributed to royaltiesa development agreement and transitional service fees resulting from the diabetes business divestiture. The royalties and transitional service fees were $64 million and $267 million for the three months and nine months ended September 30, 2014, respectively. No significant transitional service fees are expected in the future. See “Item 1. Financial Statements—Note 3. Alliances” for further details.
Pension settlement charges were recognized after determining that the annual lump sum payments will likely exceed the annual interest and service costs for certain pension plans, including the primary U.S. pension plan. The charges include the acceleration of a portion of unrecognized actuarial losses and will likely occur in the future. See “Item 1. Financial Statements—Note 17.15. Pension and Postretirement Benefit Plans” for further details.
Other includes a $23 million fee to obtain consent from BMS's joint venture partners in China in connection with the diabetes business divestiture in the third quarter of 2014 and a $45 million loss on debt redemptions in the first quarter of 2014.

Income Taxes
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 2013 2014 20132015 2014
Earnings Before Income Taxes$1,008
 $818
 $2,441
 $2,022
$1,448
 $985
Provision for Income Taxes276
 126
 439
 177
249
 49
Effective tax rate27.4% 15.4% 18.0% 8.8%17.2% 5.0%

Discrete tax benefits attributed to divestiture transactions, research and development charges and other specified items reduced the effective income tax rates by 3.6% and 18.0% in the three months ended March 31, 2015 and 2014, respectively. Favorable earnings mix accounted for the remaining reduction in effective tax rates. The applicable R&D tax credit legislation was not extended as of March 31 in the current or prior period, therefore these tax credits were not considered in estimating the annual effective tax rates were impacted by several factors including unfavorable earnings mix between high and low tax jurisdictions, the timing of the extension for the research and development credit and look through exception legislation and discrete tax benefits.in both periods.

See “Item 1. Financial Statements—Note 86. Income Taxes” for further discussion.


3429



Non-GAAP Financial Measures

Our non-GAAP financial measures, including non-GAAP earnings and related EPS information, are adjusted to exclude certain costs, expenses, gains and losses and other specified items that due to their significant and/or unusual nature are evaluated on an individual basis. Similar charges or gains for some of these items have been recognized in prior periods and it is reasonably possible that they could reoccur in future periods. Non-GAAP information is intended to portray the results of our baseline performance which include the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis and to enhance an investor’s overall understanding of our past financial performance and prospects for the future. For example, non-GAAP earnings and EPS information is an indication of our baseline performance before items that are considered by us to not be reflective of our ongoing results. In addition, this information is among the primary indicators we use as a basis for evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting for future periods. This information is not intended to be considered in isolation or as a substitute for net earnings or diluted EPS prepared in accordance with GAAP.

Specified items were as follows:
 Three Months Ended September 30, Nine Months Ended September 30,
Dollars in Millions2014 2013 2014 2013
Accelerated depreciation, asset impairment and other shutdown costs$36
 $—
 $120
 $—
Amortization of acquired Amylin intangible assets—
 137
 —
 412
Amortization of Amylin alliance proceeds—
 (68) —
 (202)
Amortization of Amylin inventory adjustment—
 —
 —
 14
Cost of products sold36
 69
 120
 224
        
Additional year of Branded Prescription Drug Fee96
 —
 96
 —
Process standardization implementation costs2
 4
 8
 6
Marketing, selling and administrative98
 4
 104
 6
        
Upfront, milestone and other payments65
 —
 228
 —
IPRD impairments—
 —
 343
 —
Research and development65
 —
 571
 —
        
Provision for restructuring35
 6
 72
 212
Gain on sale of product lines, businesses and assets(315) —
 (562) —
Pension curtailments, settlements and special termination benefits28
 37
 137
 136
Acquisition and alliance related items(a)
39
 —
 72
 (10)
Litigation charges/(recoveries)10
 —
 12
 (23)
Loss on debt redemption—
 —
 45
 —
Upfront, milestone and other licensing receipts—
 —
 —
 (14)
Other (income)/expense(203) 43
 (224) 301
        
Increase/(decrease) to pretax income(4) 116
 571
 531
Income taxes on items above33
 (40) (248) (191)
Increase to net earnings$29
 $76
 $323
 $340
 Three Months Ended March 31,
Dollars in Millions2015 2014
Cost of products sold(a)
$34
 $45
    
Marketing, selling and administrative(b)
1
 3
    
Upfront, milestone and other payments162
 15
IPRD impairments—
 33
Research and development162
 48
    
Provision for restructuring12
 21
Gain on sale of product lines, businesses and assets(152) (259)
Pension curtailments, settlements and special termination benefits27
 64
Acquisition and alliance related items(36) 16
Litigation charges14
 25
Out-licensed intangible asset impairment13
 —
Loss on debt redemption—
 45
Other (income)/expense(122) (88)
    
Increase to pretax income75
 8
Income taxes on items above(68) (179)
Increase/(Decrease) to net earnings$7
 $(171)
(a)Includes $16 millionSpecified items in cost of additional year of Branded Prescription Drug Fee.products sold are accelerated depreciation, asset impairment and other shutdown costs.
(b)Specified items in marketing, selling and administrative are process standardization implementation costs.

The reconciliations from GAAP to Non-GAAP were as follows:
Three Months Ended September 30, Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions, except per share data2014 2013 2014 20132015 2014
Net Earnings Attributable to BMS used for Diluted EPS Calculation – GAAP$721
 $692
 $1,991
 $1,837
$1,186
 $937
Less Specified Items29
 76
 323
 340
Specified Items7
 (171)
Net Earnings used for Diluted EPS Calculation – Non-GAAP$750
 $768
 $2,314
 $2,177
$1,193
 $766
          
Average Common Shares Outstanding – Diluted1,670
 1,662
 1,668
 1,659
1,676
 1,666
          
Diluted Earnings Per Share – GAAP$0.43
 $0.42
 $1.19
 $1.11
$0.71
 $0.56
Diluted EPS Attributable to Specified Items0.02
 0.04
 0.20
 0.20
—
 (0.10)
Diluted Earnings Per Share – Non-GAAP$0.45
 $0.46
 $1.39
 $1.31
$0.71
 $0.46

3530



FINANCIAL POSITION, LIQUIDITY, AND CAPITAL RESOURCES


Our net cash/(debt)cash position was as follows:
Dollars in MillionsSeptember 30,
2014		 December 31,
2013		March 31,
2015		 December 31,
2014
Cash and cash equivalents$4,851
 $3,586
$6,294
 $5,571
Marketable securities – current2,370
 939
1,313
 1,864
Marketable securities – non-current4,328
 3,747
4,279
 4,408
Cash, cash equivalents and marketable securities11,549
 8,272
11,886
 11,843
Short-term borrowings and current portion of long-term debt(401) (359)
Short-term borrowings(330) (590)
Long-term debt(7,267) (7,981)(7,127) (7,242)
Net cash/(debt) position$3,881
 $(68)
Net cash position$4,429
 $4,011

Cash, cash equivalents and marketable securities held in the U.S. were approximately $2.4$3.5 billion at September 30, 2014.March 31, 2015. Most of the remaining $9.1$8.4 billion is held primarily in low-tax jurisdictions and is attributable to earnings that are expected to be indefinitely reinvested offshore. Cash repatriations are subject to restrictions in certain jurisdictions and may be subject to withholding and additional U.S. income taxes. We believe that our existing cash, cash equivalents and marketable securities together with cash generated from operations will be sufficient to satisfy our normal cash requirements for at least the next few years, including dividends, capital expenditures, milestone payments and working capital.

In February 2014, we sold Management continuously evaluates the Company’s capital structure to AstraZeneca substantially all ofensure the diabetes business comprising our alliance with them, resulting in $3.5 billion of cash flow (excluding royalties) in the nine months ended September 30, 2014. We also redeemed our 5.45% Notes due 2018 in their entirety. The outstanding principal amount of the notes was $582 million. Management periodically evaluatesCompany is financed efficiently.  This includes potential opportunities to repurchase certain debt securities, and terminate certain interest rate swap contracts prior to their maturity. No commercial paper borrowingsmaturity and access the capital markets, subject to market conditions.

Dividend payments were outstanding$623 million in 2015 and $605 million in 2014. Dividends declared per common share were $0.37 in 2015 and $0.36 in 2014. Dividend decisions are made on a quarterly basis by our Board of Directors. Capital expenditures were approximately $500 million during each of the past three years and are expected to increase to approximately $1.0 billion during 2015 and 2016. The higher spending is expected as a result of September 30, 2014.expanding our biologics manufacturing capabilities and other facility-related activities. For example, we are planning to construct a new large-scale biologics manufacturing facility in Ireland that will produce multiple therapies for our growing biologics portfolio when completed in 2019.

Our investment portfolio includes non-current marketable securities, which are subject to changes in fair value as a result of interest rate fluctuations and other market factors, which may impact our results of operations. Our investment policy places limits on these investments and the amount and time to maturity of investments with any institution. The policy also requires that investments are only entered into with corporate and financial institutions that meet high credit quality standards. See “Item 1. Financial Statements—Note 108. Financial Instruments.”

Additional regulations in the U.S. could be passed in the future, which could further reduce our results of operations, operating cash flow, liquidity and financial flexibility. We continue to monitor the potential impact of the economic conditions in certain European and other countries and the related impact on prescription trends, pricing discounts, creditworthiness of our customers and our ability to collect outstanding receivables from our direct customers. Currently, we believe these economic conditions will not have a material impact on our liquidity, cash flow or financial flexibility.

We haveOur exposure towith certain European government-backed entities withhave a higher risk of default. We monitor themThese government-backed entities are monitored through economic factors including credit ratings, credit-default swap rates and debt-to-gross domestic product ratios in addition to entity specific factors. Our exposure has been reduced by factoring certain receivables. Our credit exposures in Europe may increase in the future due to reductions in our factoring arrangements and the ongoing sovereign debt crisis. Our credit exposure to trade receivables in Greece, Portugal, Italy and Spain was $122approximately $140 million at September 30, 2014,March 31, 2015, of which approximately 80% was from government-backed entities. Sales of trade receivables in Italy Portugal and Spain were $357$93 million in 2014 and $379 million in 2013. Sales of receivables in Japan were $327 million in 2014 and $349 million in 2013.2015. Our factoring agreements do not allow for recourse in the event of uncollectibility and we do not retain interest to the underlying assets once sold.

We continue to manage our operating cash flows by focusing on working capital items that are most directly affected by changes in sales volume, such as receivables, inventories and accounts payable.
Dollars in MillionsSeptember 30,
2014		 December 31,
2013
Net trade receivables$1,823
 $1,690
Inventories1,565
 1,498
Accounts payable(2,568) (2,559)
Total$820
 $629

36




Credit Ratings

Moody’s Investors ServiceBMS's long-term and short-term credit ratings assigned by Moody's Investors Service are A2 and Prime-1, respectively, and theirwith a negative long-term credit outlook is negative. Standard & Poor’soutlook. BMS's long-term and short-term credit ratings assigned by Standard & Poor's are A+ and A-1+, respectively, and theirwith a stable long-term credit outlook is stable. Fitch'soutlook. BMS's long-term and short-term credit ratingsassigned by Fitch are A- and F2, respectively, and long termwith a stable long-term credit outlook is negative. Our credit ratings are considered investment grade.outlook. Our long-term ratings reflect the agencies' opinion that we have a low default risk but are somewhat susceptible to adverse effects of changes in circumstances and economic conditions. Our short-term ratings reflect the agencies' opinion that we have good to extremely strong capacity for timely repayment. Any credit rating downgrade may affect the interest rate of any debt we may incur, the fair market value of existing debt and our ability to access the capital markets generally.

31



Cash Flows

The following is a discussion of cash flow activities:
Nine Months Ended September 30,Three Months Ended March 31,
Dollars in Millions2014 20132015 2014
Cash flow provided by/(used in):      
Operating activities$2,576
 $2,135
$626
 $617
Investing activities865
 (257)754
 2,212
Financing activities(2,206) (1,779)(682) (1,192)

Operating Activities

Cash flow from operating activities represents the cash receipts and disbursements from all of our activities other than investing and financing activities. Operating cash flow is derived by adjusting net earnings for noncontrolling interest, non-cash operating items, gains and losses attributed to investing and financing activities and changes in operating assets and liabilities resulting from timing differences between the receiptreceipts and payments of cash and when the transactions are recognized in our results of operations. As a result, changes in cash from operating activities reflect the timing of cash collections from customers and alliance partners; payments to suppliers, alliance partners and employees; pension contributions; and tax payments in the ordinary course of business.

The $441 million increase incomparable amount of cash provided by operating activities compared to 2013 was primarily attributable to:

Higher operating cash flow attributed tofrom increased sales, of Eliquis, Yervoy, Sprycel and Orencia, the timing of payments with alliance partners and other working capital requirements in 2014 by approximately $600 million;
2015.
Lower pension contributionsOffset by:
Proceeds from the diabetes business divestiture allocated to supply and annual employee bonus paymentsR&D arrangements in 2014 by approximately $200 million;
Lower litigation and restructuring payments in 2014 by approximately $200 million.

Partially offset by:
Lower upfront and contingent milestone proceeds from alliances in 2014 by approximately $500 million.($275 million).

Investing Activities

Cash requirements from investing activities include cash used for business acquisitions, manufacturing and facility-related capital expenditures and purchases of marketable securities with maturities greater than 90 days reduced by proceeds from business divestitures and the sale and maturity of marketable securities.

The $1.1$1.5 billion increasedecrease in cash provided by investing activities compared to 20132014 was primarily attributable to:

Proceeds of $3.4 billionLower proceeds resulting from the diabetes business divestituredivestitures of $2.9 billion ($200 million in 2014;2015 and $3.1 billion in 2014).
Partially offset by:
Higher net proceeds from sales, purchases and maturities of marketable securities in 2014 ($2.1 billion) following the diabetes business divestiture in 2014;
Cash used to acquire iPierian was $175 million in 2014.of approximately $1.4 billion.

Financing Activities

Cash requirements from financing activities include cash used to pay dividends, repurchase common stock and repay long-term debt and other borrowings reduced by proceeds from the exercise of stock options and issuance of long-term debt and other borrowings.

The $427$510 million increasedecrease in cash used in financing activities compared to 20132014 was primarily attributable to:

Net commercial paper borrowings were $470 million in 2013 (none in 2014).
RepaymentsLong-term net debt repayment of long-term debt were $676 million in 2014 and $597(none in 2015).
Partially offset by:
Lower short-term borrowings of $181 million in 2013.2015, consisting primarily of changes in bank overdrafts.
Dividend payments were $1.8 billion in 2014 and $1.7 billion in 2013. Dividends declared per common share were $1.08 in 2014 and $1.05 in 2013. Dividend decisions are made on a quarterly basis by our Board of Directors.
Cash used to repurchase common stock was $433 million in 2013 (none in 2014).
Proceeds from stock option exercises were $118 million in 2014 (excluding $111 million of excess tax benefits) and $378 million in 2013 (excluding $105 million of excess tax benefits). These proceeds will vary from period to period based on fluctuations in the market value of our stock relative to the exercise price of the stock options and other factors.

3732




CRITICAL ACCOUNTING POLICIES

The preparation of financial statements requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of revenue and expenses. Our critical accounting policies are those that significantly impact our financial condition and results of operations and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of this uncertainty, actual results may vary from these estimates. For a discussion of our critical accounting policies, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 20132014 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies during the ninethree months ended September 30, 2014March 31, 2015.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q (including documents incorporated by reference) and other written and oral statements we make from time to time contain certain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the fact they use words such as “should”, “expect”, “anticipate”, “estimate”, “target”, “may”, “project”, “guidance”, “intend”, “plan”, “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. One can also identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes to differ materially from current expectations. These statements are likely to relate to, among other things, our goals, plans and projections regarding our financial position, results of operations, cash flows, market position, product development, product approvals, sales efforts, expenses, performance or results of current and anticipated products and the outcome of contingencies such as legal proceedings and financial results, which are based on current expectations that involve inherent risks and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years. We have included important factors in the cautionary statements included in this report and in the 20132014 Annual Report on Form 10-K, particularly under “Item 1A. Risk Factors,” that we believe could cause actual results to differ materially from any forward-looking statement.

Although we believe we have been prudent in our plans and assumptions, no assurance can be given that any goal or plan set forth in forward-looking statements can be achieved and readers are cautioned not to place undue reliance on such statements, which speak only as of the date made. We undertake no obligation to release publicly any revisions to forward-looking statements as a result of new information, future events or otherwise.

3833



Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

For a discussion of our market risk, see “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” in our 20132014 Annual Report on Form 10-K.

Item 4. CONTROLS AND PROCEDURES

Management, with the participation of the Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures. Based on their evaluation, as of the end of the period covered by this Form 10-Q, the Chief Executive Officer and Chief Financial Officer have concluded that such disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective.

There were no changes in the Company’s internal control over financial reporting during the quarter ended September 30, 2014March 31, 2015 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II—OTHER INFORMATION

Item 1. LEGAL PROCEEDINGS

Information pertaining to legal proceedings can be found in “Item 1. Financial Statements—Note 1917. Legal Proceedings and Contingencies,” to the interim consolidated financial statements, and is incorporated by reference herein.


Item 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in the Company’s 20132014 Annual Report on Form 10-K.

3934



Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The following table summarizes the surrenders of our equity securities during the ninethree months ended September 30, 2014:March 31, 2015:
 
Period
Total Number of
Shares Purchased(a)
 
Average 
Price Paid
per Share(a)
 
Total Number of
    Shares Purchased as    
Part of Publicly
Announced Plans or
Programs(b)
 
Approximate Dollar
    Value of Shares that    
May Yet Be
Purchased Under the
Plans or Programs(b)
Dollars in Millions, Except Per Share Data       
January 1 to 31, 201447,745
 $53.20
 —
 $1,368
February 1 to 28, 201417,787
 $51.66
 —
 $1,368
March 1 to 31, 20142,541,287
 $54.12
 —
 $1,368
Three months ended March 31, 20142,606,819
   —
  
April 1 to 30, 201410,190
 $51.63
 —
 $1,368
May 1 to 31, 201435,296
 $49.81
 —
 $1,368
June 1 to 30, 201412,703
 $49.15
 —
 $1,368
Three months ended June 30, 201458,189
   —
  
July 1 to 31, 201415,505
 $48.41
 —
 $1,368
August 1 to 31, 20145,111
 $49.56
 —
 $1,368
September 1 to 30, 20146,826
 $51.16
 —
 $1,368
Three months ended September 30, 201427,442
   —
  
Nine months ended September 30, 20142,692,450
   —
  
Period
Total Number of
Shares Purchased(a)
 
Average 
Price Paid
per Share(a)
 
Total Number of
    Shares Purchased as    
Part of Publicly
Announced Plans or
Programs(b)
 
Approximate Dollar
    Value of Shares that    
May Yet Be
Purchased Under the
Plans or Programs(b)
Dollars in Millions, Except Per Share Data       
January 1 to 31, 201533,737
 $59.51
 —
 $1,368
February 1 to 28, 20159,178
 $60.50
 —
 $1,368
March 1 to 31, 20151,825,224
 $63.41
 —
 $1,368
Three months ended March 31, 20151,868,139
   —
  
 
(a)Reflects the shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive program.
(b)In May 2010, the Board of Directors authorized the repurchase of up to $3.0 billion of common stock.  In June 2012, the Board of Directors increased its authorization for the repurchase of stock by an additional $3.0 billion. The stock repurchase program does not have an expiration date and we may consider future repurchases.

4035



Item 6. EXHIBITS

Exhibits (listed by number corresponding to the Exhibit Table of Item 601 in Regulation S-K).
 
Exhibit No. Description
3a.Bylaws of Bristol-Myers Squibb Company, as amended as of September 16, 2014 (incorporated herein by reference to Exhibit 3.1 to the Form 8-K dated September 16, 2014 and filed on September 19, 2014).
12. Computation of Earnings to Fixed Charges.
31a. Section 302 Certification Letter.
31b. Section 302 Certification Letter.
32a. Section 906 Certification Letter.
32b. Section 906 Certification Letter.
101. 
The following financial statements from the Bristol-Myers Squibb Company Quarterly Report on Form 10-Q for the quarter ended September 30, 2014,March 31, 2015, formatted in Extensible Business Reporting Language (XBRL):
(i) consolidated statements of earnings, (ii) consolidated statements of comprehensive income and retained earnings, (iii) consolidated balance sheets, (iv) consolidated statements of cash flows, and (v) the notes to the consolidated financial statements.
  
*        Indicates, in this Form 10-Q, brand names of products, which are registered trademarks not solely owned by the Company or its subsidiaries. Byetta, Bydureon, Myalept and Symlin are trademarks of Amylin Pharmaceuticals, LLC and AstraZeneca Pharmaceuticals LP; Farxiga/Xigduo andOnglyza/Kombiglyze are trademarks of AstraZeneca AB (PUBL),; Myalept is a trademark of Aegerion Pharmaceutical, Inc.; Erbitux is a trademark of ImClone LLC; Avapro/Avalide (known in the EU as Aprovel/Karvea) and Plavix are trademarks of Sanofi; Abilify is a trademark of Otsuka Pharmaceutical Co., Ltd.; TruvadaTybost is a trademark of Gilead Sciences, Inc.; Gleevec is a trademark of Novartis AG; Atripla is a trademark of Bristol-Myers Squibb and Gilead Sciences, LLC andLLC; Reglan is a trademark of ANIP Acquisition Company.Company and Prostvac is a trademark of Bavarian Nordic A/S. Brand names of products that are in all italicized letters, without an asterisk, are registered trademarks of BMS and/or one of its subsidiaries.

4136



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. 
   
BRISTOL-MYERS SQUIBB COMPANY
(REGISTRANT)
    
Date:October 24, 2014April 28, 2015 By:/s/ Lamberto Andreotti
    
Lamberto Andreotti
Chief Executive Officer
    
Date:October 24, 2014April 28, 2015 By:/s/ Charles Bancroft
    
Charles Bancroft
Chief Financial Officer

4237